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Conﬂicts	  of	  Interest	  
•  I	  do	  not	  receive	  salary	  compensa,on	  from	  any	  
for-­‐proﬁt	  companies.	  	  
•  I	  do	  some	  consul,ng	  work	  for	  free,	  i.e.	  I	  do	  not	  
accept	  $$$	  as	  salary	  from	  anyone	  other	  than	  
my	  current	  employer,	  CSHL.	  
	  
•  Any	  revenue	  that	  I	  earn	  from	  providing	  medical	  
care	  is	  donated	  to	  UFBR	  for	  gene,cs	  research.	  
Stan	  Nelson,	  Clinical	  Applica,ons	  
•  Exome	  seq	  –	  compe,ng	  w/	  current	  paradigms	  
•  Clinical	  exome	  seq	  –	  4-­‐12	  week	  turnaround	  ,me,	  UCLA	  has	  
a	  Genomics	  Data	  Board	  
•  Claims	  50%	  diagnosis	  rate.	  	  But	  ﬁnding	  many	  de	  novo	  
muta,ons,	  with	  N=1	  &	  many	  novel	  gene	  discoveries.	  
•  TCF4	  –	  Pi]	  Hopkins	  Syndrome	  
•  Duchenne	  Muscular	  Dystrophy	  –	  developmental	  delay	  but	  
also	  diagnos,c	  delay.	  
•  Walker	  Warburg	  Syndrome	  
•  Possible	  Juvenile	  ALS	  case	  
•  Technology	  issues,	  with	  coverage	  and	  mis-­‐alignment	  stuﬀ.	  
How	  does	  a	  technology	  spread	  and	  get	  
implemented	  clinically?	  
•  WGS	  with	  Sanger	  sequencing	  ~2001	  –	  Venter	  and	  Collins/Lander	  
teams	  
	  
•  Exon	  capture	  and	  sequencing	  with	  short-­‐read	  sequencing	  techology	  
~2007.	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  Smith	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  MJ,	  Albert	  TJ,	  Hannon	  GJ,	  McCombie	  WR.	  Genome-­‐wide	  
in	  situ	  exon	  capture	  for	  selec,ve	  resequencing.	  Nature	  gene*cs	  2007,	  
39:1522-­‐1527.	  
	  
Albert	  TJ,	  Molla	  MN,	  Muzny	  DM,	  Nazareth	  L,	  Wheeler	  D,	  Song	  X,	  
Richmond	  TA,	  Middle	  CM,	  Rodesch	  MJ,	  Packard	  CJ,	  Weinstock	  GM,	  
Gibbs	  RA.	  	  Direct	  selec,on	  of	  human	  genomic	  loci	  by	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  Nature	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Evolu,on	  and	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  of	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  and	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  Genome”	  Sequencing	  
2008	  
Ng	  PC,	  Levy	  S,	  Huang	  J,	  Stockwell	  TB,	  Walenz	  BP,	  Li	  K,	  Axelrod	  N,	  Busam	  DA,	  Strausberg	  RL,	  
Venter	  JC:	  Gene,c	  varia,on	  in	  an	  individual	  human	  exome.	  PLoS	  gene*cs	  2008,	  4:e1000160.	  
	  
2009	  
	  
Ng	  SB,	  Turner	  EH,	  Robertson	  PD,	  Flygare	  SD,	  Bigham	  AW,	  Lee	  C,	  Shaﬀer	  T,	  Wong	  M,	  
Bha]acharjee	  A,	  Eichler	  EE,	  et	  al:	  Targeted	  capture	  and	  massively	  parallel	  sequencing	  of	  12	  
human	  exomes.	  Nature	  2009,	  461:272-­‐276.	  
	  
Choi	  M,	  Scholl	  UI,	  Ji	  W,	  Liu	  T,	  Tikhonova	  IR,	  Zumbo	  P,	  Nayir	  A,	  Bakkaloglu	  A,	  Ozen	  S,	  Sanjad	  S,	  
et	  al:	  Gene,c	  diagnosis	  by	  whole	  exome	  capture	  and	  massively	  parallel	  DNA	  sequencing.	  
Proc	  Natl	  Acad	  Sci	  U	  S	  A	  2009,	  106:19096-­‐19101.	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“Whole	  Genome”	  Sequencing,	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  KP,	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  N,	  
Bamshad	  M,	  et	  al:	  Analysis	  of	  gene,c	  inheritance	  in	  a	  family	  quartet	  by	  whole-­‐genome	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  Science	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By	  July	  2012	  –	  Explosion	  of	  Research	  	  
•  As	  of	  July	  2012,	  540	  ar,cles	  in	  Pubmed	  with	  
word	  “exome”	  and	  “human”	  in	  them.	  	  
•  And	  358	  ar,cle	  with	  “whole	  human	  genome	  
sequencing	  &	  disease”	  in	  them.	  
•  Hundreds	  of	  new	  muta,ons	  in	  known	  disease	  
genes,	  and	  dozens	  of	  new	  disease	  genes	  
discovered.	  
Discov	  Med.	  2011	  Jul;12(62):41-­‐55.	  
Story	  #	  1	  
Exome	  sequencing	  of	  one	  pedigree	  in	  
a	  research	  setng.	  
Figure 1. The pedigree structure is shown, with corresponding ID 
numbers. The three subjects in the pedigree affected with ADHD are 
shaded. Only 84060 has the idiopathic hemolytic anemia. The mother, 
father and two sons were sequenced. The two sisters in the family 
declined to participate in the study, thus their phenotype status is 
unknown and marked as “?”. 
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Exome	  Sequencing	  performed	  early	  
2010	  
While	  analyzing	  the	  exome	  data,	  research	  parCcipant	  (age	  
~24)	  informs	  me	  that	  he	  recently	  had	  his	  spleen	  removed!	  
	  
He	  has	  idiopathic	  hemolyCc	  anemia,	  since	  childhood.	  
	  
Although	  I	  am	  not	  his	  physician,	  I	  sCll	  feel	  an	  ethical	  and	  
moral	  obligaCon	  to	  try	  to	  ﬁgure	  out	  what	  is	  going	  on.	  
Compound	  Heterozygote	  in	  PKLR,	  with	  
each	  muta,on	  inherited	  from	  one	  
parent.	  
!
Some	  Addi,onal	  Data	  to	  support	  the	  
causa,on	  of	  these	  variants	  for	  
idiopathic	  hemoly,c	  anemia.	  
Structural	  Modeling	  is	  also	  consistent	  with	  deleterious	  eﬀects	  of	  these	  muta,ons.	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Secondary Variants in Individuals Undergoing Exome
Sequencing: Screening of 572 Individuals Identifies
High-Penetrance Mutations in Cancer-Susceptibility Genes
Jennifer J. Johnston,1,7 Wendy S. Rubinstein,1,2,3,7,8 Flavia M. Facio,1 David Ng,1 Larry N. Singh,1
Jamie K. Teer,1,4 James C. Mullikin,1,4,5,6 and Leslie G. Biesecker1,4,*
Genome- and exome-sequencing costs are continuing to fall, and many individuals are undergoing these assessments as research partic-
ipants and patients. The issue of secondary (so-called incidental) findings in exome analysis is controversial, and data are needed on
methods of detection and their frequency. We piloted secondary variant detection by analyzing exomes for mutations in cancer-suscep-
tibility syndromes in subjects ascertained for atherosclerosis phenotypes. We performed exome sequencing on 572 ClinSeq participants,
and in 37 genes, we interpreted variants that cause high-penetrance cancer syndromes by using an algorithm that filtered results on the
basis of mutation type, quality, and frequency and that filteredmutation-database entries on the basis of defined categories of causation.
We identified 454 sequence variants that differed from the human reference. Exclusions were made on the basis of sequence quality (26
variants) and high frequency in the cohort (77 variants) or dbSNP (17 variants), leaving 334 variants of potential clinical importance.
These were further filtered on the basis of curation of literature reports. Seven participants, four of whom were of Ashkenazi Jewish
descent and three of whom did not meet family-history-based referral criteria, had deleterious BRCA1 or BRCA2 mutations. One
participant had a deleterious SDHCmutation, which causes paragangliomas. Exome sequencing, coupled with multidisciplinary inter-
pretation, detected clinically important mutations in cancer-susceptibility genes; four of such mutations were in individuals without
a significant family history of disease.We conclude that secondary variants of high clinical importance will be detected at an appreciable
frequency in exomes, and we suggest that priority be given to the development of more efficient modes of interpretation with trials in
larger patient groups.
Introduction
High-throughput sequencing is effective for elucidating
the cause of heritable disorders1 and for interrogating
many genes in high-risk individuals.2 The number of
research subjects undergoing exome or genome se-
quencing is rapidly increasing. Apart from the identifica-
tion of the mutation causing the disorder for which the
sequencing was performed (i.e., the primary variant),
genome and exome sequencing have the potential to iden-
tify other clinically important results (i.e., secondary or so-
called incidental variants). The number of clinically impor-
tant secondary variants in human genomes is substantial.
Each genome in the 1000 Genomes Project has 50–100
variants in disease-associated genes,3 and a screen4 of 104
exomes for 448 severe recessive diseases found an average
carrier burden of 2.8 variants per person. Recommended
interventions for highly penetrant conditions might
include prophylactic cancer surgery and screening,5 im-
plantation of a cardioverter defibrillator,6 and pharmaco-
genomic7 and reproductive decision making.8
The potential ability to identify secondary variants has
led to controversy regarding whether these variants should
be sought, and if they are sought or accidentally encoun-
tered, whether and how these variants should be returned
to patients or research subjects.9–11 To shed light on this
controversy, we set out to develop approaches to the anal-
ysis and return of whole-exome sequencing (WES) results
for secondary (or so-called incidental) variants in genes
associated with high-penetrance cancer-susceptibility
syndromes in a cohort not ascertained for these condi-
tions. We piloted these approaches on 572 ClinSeq12
participants and report the yield, utility, and limitations
of this strategy. Finally, we discuss the implications of
these findings for researchers generating these kinds of
data and considering whether—and how—to return such
results to study participants.
Subjects and Methods
Study Participants
ClinSeq participants were 45–65 years of age and gave consent
for genome and exome sequencing and the return of results.12
They were selected for a range of atherosclerosis phenotypes, but
not for personal or family histories of cancer. Family history,
including ethnicity, was collected during the initial evaluation.
1Genetic Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA; 2Department of
Medicine, Division of Genetics, NorthShore University HealthSystem, Evanston, IL 60201, USA; 3Department of Medicine, University of Chicago Pritzker
School of Medicine, Chicago, IL 60637, USA; 4National Institutes of Health Intramural Sequencing Center, National Human Genome Research Institute,
National Institutes of Health, Bethesda, MD 20852, USA; 5Genome Technology Branch, National Human Genome Research Institute, National Institutes of
Health, Bethesda, MD 20852, USA
6On behalf of the National Institutes of Health Intramural Sequencing Center Comparative Sequencing Program
7These authors contributed equally to this work
8Present address: National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD 20894, USA
*Correspondence: leslieb@helix.nih.gov
DOI 10.1016/j.ajhg.2012.05.021. !2012 by The American Society of Human Genetics. All rights reserved.
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rates.4,42 In addition, the pathogenicity determination of
variants can vary among LSDBs and HGMD, making inter-
pretation of these data challenging. Of the 451 variants
identified in this study, nine that were identified as
pathogenic in HGMD were reclassified as benign on the
basis of frequency in controls. Fifty-nine other variants
identified as pathogenic in HGMD were assigned patho-
genicity scores between 2 and 4 on the basis of co-occur-
rence with known pathogenic mutations, limited infor-
mation on causality, or association to a diseas other
than a high-penetrance cancer syndrome. Two variants
(c.1145G>A [p.Gly382Asp] and c.494A>G [p.Tyr165Cys]
in MUTYH) assessed here as class 5 were identified in
HGMD as disease-associated polymorphisms rather
than disease-causing mutations possibly on the basis of
their high allele frequency in the general population.
Both of these variants were also included in dbSNP as
rs36053993 and rs34612342. dbSNP includes both patho-
genic and nonpathogenic variants. We observed that the
pathogenicity determination of a give variant was g ner-
ally more conservative in LSDBs than in HGMD. Of the
nine variants previously classified as pathogenic in an
LSDB, we assigned eight of those nine variants pathoge-
nicity scores of 5. Furthermore, n variant hat was ot
identifi d as pathogenic in the corresponding LSDB was
assigned a pathogenicity score of 5. The 1000 Genomes
dataset3 does not include phenotypic data, so deriving
conclusions of causation from those data is difficult. These
complexities of determining causality are not novel and
have bedeviled single-gene testing laboratories for years.
However, the scale of WES greatly magnifies these issues
and argues for increased efforts to improve mutation data-
bases before genomic screening of healthy individuals
moves into the clinical realm. Cohorts such as ClinSeq,
which have robust phenotypic data and the ability to
perform iterative clinical research, should be useful for
the assessment of the pathogenicity of variants and the
improvement of these databases.
We detected eight cases of a high-penetrance autosomal-
dominant tumor or cancer syndrome among 572 persons
undergoing WES. The high rate of breast and ovarian
cancer susceptibility is attributable in part to the large
proportion (~17%) of Ashkenazi Jewish participants in
ClinSeq and the 2.5% prevalence of BRCA1 or BRCA2
founder mutations among that group. However, three
participants with BRCA1 or BRCA2 mutations were not of
Ashkenazi Jewish heritage, and two of these individuals
did not meet NCCN guidelines for further risk assessment.
Additionally, the individual with the SDHC mutation did
not have a family history of paraganglioma. In all, at least
three of the seven individuals with class 5 variants had no
indication from family history that they were at an
increased risk of developing familial cancer.
This study has a number of limitations. Like t e early
dopters of ge etic testing in specialty clinics or t ose
undergoing direct-to-consumer genetic testing, ClinSeq
subjects are not representative of the general population.
The cohort has a high average income and educational
level an exhibits a high degree of curiosity and motiva-
tion regarding genetic testing and research.43 Another
potential source of bias is that some ClinSeq participants
enrolled on the basis of family history. This effect is
evident in at least one other rare disease in the ClinSeq
cohort (Biesecker et al., unpublished data). It should not
be concluded that the overall prevalence of pathogenic
mutations in this cohort is representative of the general
population. A further complication might be the average
age of our cohort. The average age of 58 years might cause
a reduced number of high-penetrance cancer alleles in the
sample because many of these variants cause morbidity
Table 3. Participant Information for Pathogenic Variants Identified in BRCA1 and BRCA2
Gene
Mutations and RefSeq
Accession Numbers Sex Age Ethnicity
Mutation
Results
Prior to
Study
BRCAPRO
Score
Met
NCCN
Guidelines
Met USPSTF
Referral Criteria
(Women Only)
BRCA1 c.547þ2T>Aa (NM_007294.3) female 48 y ars northern European yes N/A yes yes
BRCA1 c.68_69del
(p.Glu23Valfs*17) (NM_007294.3)
male 61 years Ashkenazi Jewish no 0.3% no N/A
BRCA2 c.5482_5486 del
(p.L s1828Valfs*4) (NM_000059.3)
female 56 years Japanese no 0.0% no no
BRCA2 c.5946del
(p.Ser1982Argfs*22) (NM_000059.3)
male 57 years Ashkenazi Jewish no 0.9% yes N/A
BRCA2 c.5946del
(p.Ser1982Argfs*22) (NM_000059.3)
male 60 years Ashkenazi Jewish no 42.3% yes N/A
BRCA2 c.5946del
(p.Ser1982Argfs*22) (NM_000059.3)
male 55 years Ashkenazi Jewish yes N/A yes N/A
BRCA2 c.8297del
(p.Thr2766Asnfs*11) (NM_000059.3)
male 59 years Irish no 0.6% no N/A
The following abbreviations are used: NCCN, National Comprehensive Cancer Network; and USPSTF, U.S. Preventive Services Task Force.
aThe predicted protei alt rati n is not provided for this splice-site mutation.
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•  Why	  does	  it	  ma]er?	  
•  Your	  child	  has	  a	  “terminal	  dele,on”	  ???	  	  	  
•  The	  “incidentalome”–	  just	  putng	  “-­‐ome”	  on	  the	  end	  does	  not	  make	  this	  
interes,ng	  or	  useful!	  
•  There	  is	  NOTHING	  “Incidental”	  about	  Unrelated,	  Unan,cipated	  or	  Secondary	  
Findings.	  
	  
•  Sequencing	  a	  bunch	  of	  exomes	  and	  ﬁnding	  random	  rare	  variants	  MIGHT	  be	  
“incidental”,	  but	  actually	  proving	  that	  these	  variants	  CAUSE	  the	  disease	  is	  NOT	  
simple	  or	  “incidental”	  or	  “accidental”	  or	  “coincidental”.	  	  
•  I	  would	  suggest	  calling	  these	  “unrelated,	  unan,cipated	  or	  secondary	  ﬁndings”,	  
rather	  than	  “incidental”.	  
•  Con,nuing	  to	  call	  these	  “incidental	  ﬁndings”	  trivializes	  the	  amount	  of	  work	  that	  
ought	  to	  go	  into	  proving	  causality,	  plus	  it	  confuses	  the	  public	  at	  large.	  Lyon,	  
Personalized	  Medicine,	  2012.	  
	  
I	  suggest	  we	  get	  rid	  of	  this	  term	  “incidental	  ﬁnding”,	  and	  replace	  
it	  with	  “secondary”,	  “unrelated”,	  or	  “unanCcipated”	  ﬁndings	  
Yet,	  it	  is	  July	  2012	  and	  my	  research	  
par,cipant	  s,ll	  has	  not	  come	  back	  to	  give	  
blood	  for	  CLIA-­‐cer,ﬁed	  results.	  Why?	  
Major	  Barriers	  to	  the	  implementa,on	  of	  Genomic	  Medicine	  in	  
the	  clinic:	  
1)  Lack	  of	  public	  educa,on	  –	  consumer	  not	  sure	  it	  ma]ers.	  
2)  Lack	  of	  physician	  knowledge	  about	  gene,cs.	  
3)  Apathy	  on	  the	  part	  of	  populace,	  as	  they	  have	  “learned”	  to	  be	  
apathe,c	  and	  to	  not	  be	  empowered	  about	  their	  own	  health.	  
4)  Refusal	  of	  insurance	  companies	  to	  pay	  for	  “not	  useful”	  
gene,c	  tes,ng.	  
5)  Focus	  in	  our	  society	  on	  Treatment,	  NOT	  on	  early	  diagnosis	  
and	  preven,on.	  
Emphasis	  Should	  be	  on	  Diagnosis	  and	  
Preven,on,	  NOT	  just	  on	  Treatment	  
•  15	  year	  old	  girl	  with	  Type	  I	  diabetes,	  hospitalized	  
dozens	  of	  ,mes	  with	  diabe,c	  ketoacidosis.	  
Millions	  spent	  to	  save	  life	  repeatedly,	  but	  very	  
li]le	  on	  therapy	  or	  educa,on	  –	  WHY?	  
•  14	  year	  old	  boy	  hospitalized	  >10	  ,mes	  with	  
pancrea,,s	  over	  >	  ten	  years.	  Finally,	  someone	  
gets	  gene,cs	  consult.	  Pa,ent	  has	  cys,c	  ﬁbrosis,	  
undiagnosed	  ,ll	  then.	  Beneﬁts	  from	  pancrea,c	  
enzyme	  supplementa,on,	  plus	  therapy	  and	  
educa,on.	  WHY	  so	  LONG	  to	  diagnose?	  
I	  would	  suggest	  that	  researchers	  working	  on	  
DNA	  samples	  from	  living	  humans	  perform	  CLIA-­‐
cer,ﬁed	  sequencing	  UP	  FRONT,	  either	  with	  
exomes	  or	  whole	  genomes,	  so	  that	  we	  can	  
return	  results	  to	  consumers,	  “pa,ents”,	  research	  
par,cipants	  and	  families.	  
	  
	  
	  
	  
One	  Conclusion	  that	  I	  started	  to	  come	  to	  from	  this	  
story	  alone:	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Family Pedigree 
prominence	  of	  eyes,	  down-­‐sloping	  palpebral	  ﬁssures,	  thickened	  
eyelids,	  large	  ears,	  beaking	  of	  nose,	  ﬂared	  nares,	  hypoplas,c	  nasal	  
alae,	  short	  columella,	  protruding	  upper	  lip,	  micro-­‐retrognathia	  
	  
Using Next Gen Seq to figure out genetic basis of a New Disease 
I	  met	  the	  en,re	  family	  on	  March	  29,	  2010	  
Photo	  of	  mother	  
with	  son	  in	  late	  1970’s	  
First	  boy.	  Called	  “a	  li]le	  old	  man”	  by	  
the	  family.	  Died	  around	  ~1	  year	  of	  
age,	  from	  cardiac	  arrhythmias.	  
This	  is	  the	  ﬁrst	  boy	  in	  the	  late	  1970’s.	  
  X-­‐chromosome	  exon	  capture	  with	  Agilent,	  
followed	  by	  Next	  Gen	  Sequencing	  with	  
Illumina.	  
  Analysis	  with	  ANNOVAR	  and	  VAAST	  (Variant	  
AnnotaCon,	  Analysis	  and	  Search	  Tool).	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Mutation 
WT 
C C C 
Pro37 
Proband  
Unaffected 
Brother 
C T T G G	  T C T C 
Ser37 
C 
T 
This is the causative mutation. There are ~6 billion 
nucleotide in a diploid human genome, but this one 
REALLY matters! 
By	  November	  2010,	  we	  had	  good	  
func,onal	  data	  in	  vitro	  (bacterially	  
expressed	  proteins)	  and	  in	  vivo	  (yeast,	  
unpublished),	  leading	  me	  to	  believe	  
we	  had	  iden,ﬁed	  the	  causa,ve	  
muta,on.	  
	  
A	  new	  mother	  in	  the	  family	  informs	  me	  
she	  is	  4	  months	  pregnant,	  with	  a	  boy!	  
The	  now	  pregnant	  mother-­‐to-­‐be	  is	  circled	  in	  red.	  
Our	  Sanger	  Sequencing	  had	  shown	  her	  to	  be	  a	  
carrier	  of	  the	  mutaCon.	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BUT,	  as	  a	  researcher,	  I	  was	  naive	  and	  ignorant	  
concerning	  the	  following	  quesCon:	  
	  
How	  do	  we	  give	  such	  research	  results	  back	  to	  
research	  parCcipants?	  
	  
MAJOR	  ISSUES	  that	  I	  learned	  about	  
•  I	  am	  a	  physician	  but	  not	  HER	  physician,	  therefore	  I	  had	  NOT	  
entered	  into	  a	  “physician-­‐pa,ent	  contract”	  with	  her.	  
•  This	  was	  not	  a	  “diagnos,c	  test”.	  This	  was	  research,	  and	  not	  
“CLIA-­‐cer,ﬁed”.	  All	  Clinical	  Diagnos,c	  Tests	  are	  regulated	  in	  
America	  with	  the	  Clinical	  Laboratory	  Improvement	  
Amendments	  act.	  
	  
•  How	  does	  one	  return	  research	  results	  to	  par,cipants	  without	  
breaking	  the	  law	  or	  doing	  something	  that	  might	  
inadvertently	  harm	  the	  person?	  
•  Please	  remember	  that	  CLIA	  was	  implemented	  to	  prevent	  
people	  from	  being	  given	  wrong	  test	  results	  (due	  to	  poor	  
quality).	  
	  
Societal	  Issues	  
 Test	  tube	  babies	  are	  a	  success	  because	  the	  ﬁrst	  baby	  born,	  
Louise	  Brown,	  was	  ﬁne	  and	  free	  of	  gene,c	  defects.	  
 Gene	  Therapy	  was	  set	  back	  by	  >10	  years	  due	  to	  the	  death	  of	  
Jesse	  Geisinger	  and	  a	  disregard	  of	  rules	  and	  regula,on	  by	  
certain	  researchers.	  
 We	  have	  Nicholas	  Volcker	  as	  a	  shining	  example	  of	  success	  with	  
WGS.	  
 But,	  we	  don’t	  want	  to	  screw	  this	  up	  with	  some	  research	  lab	  
giving	  back	  incorrect	  results	  to	  someone,	  leading	  to	  some	  
calamitous	  outcome,	  such	  as	  someone	  thinking	  they	  have	  
Hun,ngton’s	  muta,on	  when	  they	  don’t,	  and	  commitng	  
suicide.	  
Nature.	  2012	  Feb	  15;482(7385):300-­‐1	  	  
“I	  suggest	  that	  we	  change	  the	  way	  we	  collect	  and	  process	  samples	  for	  
human-­‐gene,cs	  research.	  We	  should	  create	  a	  formalized	  protocol	  akin	  to	  
the	  rigorous	  process	  that	  doctors	  and	  other	  health-­‐care	  workers	  go	  
through	  during	  any	  clinical	  lab	  test,	  which	  prac,cally	  eliminates	  the	  
chances	  of	  mistakes	  and	  mix-­‐ups.”	  
Technically,	  clinical	  grade	  DNA	  tesCng	  currently	  means	  the	  
following:	  
	  
1)  Blood	  or	  saliva	  collected	  with	  rigorous,	  automated	  sample	  
tracking.	  
2)  DNA	  isolated	  in	  a	  CLIA-­‐cer,ﬁed	  facility.	  
3)  Sequencing	  performed	  in	  a	  CLIA-­‐cer,ﬁed	  facility.	  
4)  Analysis	  performed	  with	  a	  CLIA-­‐cer,ﬁed	  bioinforma,cs	  pipeline.	  
This	  is	  what	  should	  happen	  with	  any	  sample	  with	  possible	  return	  of	  
results!!!	  
	  
Many	  barriers	  in	  the	  way	  of	  developing	  a	  
test	  at	  ARUP	  (gene,c	  laboratory	  I	  was	  
using	  in	  Utah)	  –	  in	  retrospect,	  should	  have	  
tried	  GeneDx.	  
	  
Mother	  four	  months	  pregnant	  Nov	  2010	  
	  
Baby	  born	  March	  2011.	  
	  
Aﬀected	  with	  Disease.	  
	  
He	  died	  June	  2011,	  same	  week	  as	  
publica,on	  of	  our	  paper	  in	  AJHG.	  
	  
For	  several	  reasons,	  it	  is	  not	  clear	  anything	  
would	  have	  changed	  even	  if	  she	  had	  
received	  the	  result	  during	  pregnancy.	  
	  

Proving	  Causality	  –	  MAJOR	  Problem	  with	  this	  “gold	  
rush”	  of	  singleton	  mutaCons	  
 Need	  to	  ﬁnd	  the	  EXACT	  same	  muta,on	  in	  another	  unrelated	  family,	  i.e.	  in	  a	  
diﬀerent	  gene,c	  background	  and	  environment.	  
 This	  is	  because	  we	  do	  not	  have	  breeding	  or	  introgression	  in	  human	  gene,cs!	  
 How	  did	  we	  ﬁnd	  the	  second	  family?	  
II-1 III-2 
Ogden Syndrome, in honor of where the first family 
lives, in Ogden, Utah 
What	  about	  the	  other	  women	  in	  the	  family?	  Are	  they	  
carriers?	  Once	  again,	  this	  was	  “research”.	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Results	  from	  Next	  Gen	  Seq	  requires	  
both	  Analy,c	  and	  Clinical	  Validity	  
•  Analy,cal	  Validity:	  the	  test	  is	  accurate	  with	  
high	  sensi,vity	  and	  speciﬁcity.	  
•  Clinical	  Validity:	  Given	  an	  accurate	  test	  result,	  
what	  impact	  and/or	  outcome	  does	  this	  have	  
on	  the	  person?	  
Analy,cal	  Validity	  of	  Exome	  and	  WGS?	  
	  
	  
	  
	  
•  Minimal	  Standard:	  exomes	  and	  genomes	  ought	  to	  be	  
performed	  in	  a	  CLIA-­‐cer,ﬁed	  environment	  for	  germline	  
genomic	  DNA	  from	  live	  humans	  .	  
•  Easier	  said	  than	  done	  in	  academia,	  but	  some	  companies	  oﬀer	  
this	  now:	  Illumina,	  23andMe,	  Ambry	  Gene,cs,	  and	  some	  
academic	  places	  do	  oﬀer	  this	  now:	  UCLS,	  Baylor	  and	  WashU	  for	  
exomes.	  
•  I	  do	  NOT	  think	  the	  FDA	  should	  get	  involved	  to	  regulate	  this,	  nor	  
do	  the	  results	  have	  to	  go	  through	  a	  physician,	  i.e.	  DTC	  is	  ﬁne	  as	  
long	  as	  CLIA-­‐cer,ﬁed.	  
Why	  can	  UCLA	  implement	  CLIA-­‐
cer,ﬁed	  exome	  sequencing	  so	  quickly,	  
whereas	  most	  have	  not	  or	  cannot?	  
•  Others	  doing	  this	  are:	  Baylor,	  WashU-­‐St.Louis,	  
Ambry	  Gene,cs,	  23andMe.	  
•  For	  CLIA-­‐cer,ﬁed	  WGS,	  there	  is	  Wisconsin,	  
Baylor,	  WashU-­‐St.Louis.	  
Autonomy	  vs.	  Privacy	  vs.	  Bureaucracy	  
Privacy	  
Autonomy	  
Bureaucracy	  
Vanderbilt	  	  	  	  	  	  CHOP	  	  	  	  	  ClinSeq-­‐NIH	  	  	  	  	  Gene	  Partnership	  	  	  	  	  Personal	  Genome	  Project	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  23AndMe	  
	   	   	   	   	   	   	   	   	   	  	  	  	  	  	  	  	  	  Ancestry.com	  
	  
Mapping clinical phenotype data elements to
standardized metadata repositories and controlled
terminologies: the eMERGE Network experience
Jyotishman Pathak,1 Janey Wang,2 Sudha Kashyap,2 Melissa Basford,2 Rongling Li,3
Daniel R Masys,2 Christopher G Chute1
ABSTRACT
Background Systematic study of clinical phenotypes is
important for a better understanding of the genetic basis
of human diseases and more effective gene-based
disease management. A key aspect in facilitating such
studies requires standardized representation of the
phenotype data using common data elements (CDEs)
and controlled biomedical vocabularies. In this study, the
authors analyzed how a limited subset of phenotypic
data is amenable to common definition and standardized
collection, as well as how their adoption in large-scale
epidemiological and genome-wide studies can
significantly facilitate cross-study analysis.
Methods The authors mapped phenotype data
dictionaries from five different eMERGE (Electronic
Medical Records and Genomics) Network sites studying
multiple diseases such as peripheral arterial disease and
type 2 diabetes. For mapping, standardized
terminological and metadata repository resources, such
as the caDSR (Cancer Data Standards Registry and
Repository) and SNOMED CT (Systematized
Nomenclature of Medicine), were used. The mapping
process comprised both lexical (via searching for relevant
pre-coordinated concepts and data elements) and
semantic (via post-coordination) techniques. Where
feasible, new data elements were curated to enhance
the coverage during mapping. A web-based application
was also developed to uniformly represent and query the
mapped data elements from different eMERGE studies.
Results Approximately 60% of the target data elements
(95 out of 157) could be mapped using simple lexical
analysis techniques on pre-coordinated terms and
concepts before any additional curation of terminology
and metadata resources was initiated by eMERGE
investigators. After curation of 54 new caDSR CDEs and
nine new NCI thesaurus concepts and using post-
coordination, the authors were able to map the
remaining 40% of data elements to caDSR and SNOMED
CT. A web-based tool was also implemented to assist in
semi-automatic mapping of data elements.
Conclusion This study emphasizes the requirement for
standardized representation of clinical research data using
existing metadata and terminology resources and
provides simple techniques and software for data element
mapping using experiences from the eMERGE Network.
INTRODUCTION
A principal goal of genetic research is to identify
speciﬁc genotypes that are associated with human
phenotypes. With recent advances in genotyping
technologies, even though it has become possible to
systematically ascertain large numbers of sequence
variants (eg, single-nucleotide polymorphisms) for
the complete genome of an individual, our ability to
fully understand the genetic basis of common
diseases is signiﬁcantly hindered by our inability to
precisely specify the phenotypes (ie, the outward
physical manifestation of the genotypes).1 In
particular, phenotyping at large varies greatly
between medical specialties and different organiza-
tions, and lacks the systematization and throughput
compared with large-scale genotype studies.
Hence, to address this important requirement,
the US National Institutes of Health has recently
funded projects, such as the eMERGE Network
(Electronic Medical Records and Genomics2), that
correlate whole genome scans with phenotype data
extracted from electronic medical records (EMRs).
An integral part of such efforts is to standardize the
representation of phenotypic data in a dataset.
However, in practice, biomedical research applica-
tions and clinical systems are developed indepen-
dently of each other, and therefore do not have
a common data representation structure or a data
dictionary. This results in the creation of data
elements (DEs) anew for each particular study,
even for commonly collected data such as demo-
graphics, laboratory results, and vital statistics.
Clearly, to facilitate the interpretation of such data,
it is vital to provide not only a data dictionary to
accompany the data, but also appropriate mapping
of the DEs to controlled vocabularies and termi-
nological resources to promote secondary reuse and
standardization of DEs.
The overarching goal of this work is to investigate
how a limited set of DEs, as part of the eMERGE
Network studies, can be mapped to standardized
metadata repositories and biomedical vocabularies.
In particular, we studied mapping of multiple
phenotype data dictionaries (dementia, peripheral
arterial disease, low high-density lipoprotein (HDL),
cataract, type 2 diabetes, and long QT syndrome)
from ﬁve eMERGE consortium members to existing
metadata and terminological resources including
National Cancer Institute’s (NCI’s) caDSR (Cancer
Data Standards Registry and Repository),3 Clinical
Data Interchange Standards Consortium’s
(CDISC’s) SDTM (Study Data Tabulation Model),4
NCI thesaurus (NCI-T),5 and SNOMED CT
(Systematized Nomenclature of MedicineeClinical
Terms).6 We also implemented an open-source web
services-based toolkit and repository called eleMAP7
for semi-automatic mapping of DEs to standardized
biomedical vocabularies and metadata registries.
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concept domain of the DE as w ll as i s permissible values. In
this study, we investigate four terminology and metadata
resources for apping f MERGE phenotype DEs. Our selec-
tion of these resources was guided by several factors (four A’s):
availability ( reely and publicly); accessibility (programmatic);
adoption (by the clinical rese rch community, government
and healthcare industry); and a propriateness (relevancy to
eMERGE). We dis uss th m brieﬂy in the following sections.
Cancer Data Standards Registry and Repository
The caDSR,3 developed by the NCI, deﬁnes a comprehensive set
of standardized metadata descriptors for cancer research data for
use in information collection and analysis for clinical research
questions. It provides a database and a set of application
programming interfaces (APIs) to create, edit, deploy, and ﬁnd
common data elements (CDEs). The caDSR is based on the
ISO/IEC 11179 model for metadata registration, and uses this
standard for representing information about names, deﬁnitions,
permissible values, and semantic concepts for the CDEs. Over
the past several years, various NCI ofﬁces and partner organi-
zations have developed the content for caDSR by registration of
DEs based on data standards, data collection forms, databases,
clinical applications, data exchange formats, UML models, and
vocabularies.
NCI thesaurus (NCI-T)
The NCI-T5 is a reference terminology and biomedical ontology,
developed by the NCI, that has a broad coverage of the cancer
domain, including: cancer-related diseases, ﬁndings, and abnor-
malities; anatomy; agents, drugs, and chemicals; genes and gene
products; and so on. It covers vocabulary for clinical care,
translational and basic research, and public information and
administrative activities, and provides deﬁnitions, synonyms,
and other information on nearly 10 000 cancers and related
diseases, 8000 single agents and combination therapies, and
a wide range of other topics related to cancer and biomedical
research. Comprising w80 000 concepts, NCI-T is published
monthly and is edited by a group of about 15 domain expert
editors. The terminology is accessible through web browsers,
directly through the LexEVS API,21 or by download in several
formats, including OWL-DL.22
Study Data Tabulation Model terminology (SDTM-T)
The SDTM,4 developed by the CDISC, is a standard for
submitting data tabulations of human clinical trial studies to the
Food and Drug Administration (FDA) in support of marketing
applications. It is built around the concept of observations
collected about subjects who participated in a clinical study,
where each observation can be described by a series of variables,
corresponding to a row in a dataset or table. A key element of
SDTM is the SDTM-T, which deﬁnes a standard list of values for
use in the clinical data lifecycle. Maintained and distributed as
part of NCI-T, the SDTM-Tcomprises 50 code lists withw2200
terms covering demographics, interventions, ﬁndings, events,
trial design, units, frequency, and ECG terminology.
Systematized Nomenclature of MedicineeClinical Terms (SNOMED CT)
The SNOMED CT6 is a comprehensive clinical terminology
covering most areas of clinical information such as diseases,
ﬁndings, procedures, microorganisms, and pharmaceuticals. It is
concept-oriented and has an advanced structure based on DL19
that meets most accepted criteria for a well-formed, machine-
readable terminology. Comprising more than 300 000 concepts,
SNOMED CT is one of the designated data standards for use in
US Federal government systems for electronic exchange of
clinical health information.
Methods: DE mapping
Our methods can be summarized as follows. Once the DEs have
been collected and extracted from the eMERGE data dictio-
naries, we ﬁrst apply simple lexical methods to ﬁnd a direct
correspondence between the variable and value set (ie, the
permissible values) of the DE to CDEs in the caDSR as well as to
biomedical concepts in terminologies, such as the SNOMED CT.
Note that when mapping to concepts in biomedical terminolo-
gies, our lexical matching technique primarily takes into account
pre-coordinated concepts.23 24 Hence, in situations where such
lexical queries do not result in a match, we attempt post-coor-
dinationdthat is, we compose new concepts by qualifying
existing pre-coordinated conceptsdto reﬂect the intended
semantics of the DEs. We describe the details of our methods in
the following sections.
DE mapping via pre-coordination
Our approach to mapping DEs to pre-coordinated terms and
concepts from standardized biomedical terminologies and
metadata resources is as conservative as possible. We ﬁrst try to
ﬁnd an exact string match for the DE variable. If no match is
found, we perform an approximate search by normalizing the
original search string (eg, eliminating underscores, hyphen
variations) as well as adding a wildcard (*) to the beginning and
end of the string. The entire process is automated, and the
search stops as soon as a match is found. Furthermore, if the DE
has an enumerated list of permissible values (in the data
dictionary) for its value set, we repeat the above procedure to
ﬁnd corresponding terms and concepts.
For querying the caDSR, we use the caDSR HTTP API, which
allows an application to connect to caDSR remotely and search
the database. The API provides various forms of functions for
querying the caDSR, and returns the results in a well-formed
XML document. As mentioned above, the caDSR is based on the
ISO/IEC 11179 model for metadata registration and, as a result,
decomposes the essence of a DE in well-formed parts, separating
the conceptual entity (DE concept) from its physical represen-
tation in a database (value domain). The DE concept may be
Table 5 Snapshot of Northwestern University’s type 2 diabetes data
dictionary
Variable Description Type Units Permissible values
Subject_ID Deidentified
subject’s ID
Integer
Enrollment_age Age at enrollment
in DNA biorepository
Integer
Case_control Is the subject a
case or a control?
Encoded 0¼Case; 1¼Control
Sex Subjec ’s gender Encoded M¼Male; F¼Female;
U¼Unknown
Race Subject’s race Encoded 0¼African American;
1¼American Indian; 2¼Asian;
3¼White; 4¼Native Hawaiian;
5¼Other; 6¼Unknown;
7¼Missing
Weight Subject’s weight
in kilograms
Decimal kg
Height Subject’s height
in centimeters
Decimal cm
Glucose_
measurement
Subject’s random
glucose level
Decimal mg/dl
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Phase	  I	  sites	  
1.  Vanderbilt	  Univer ity	  
2.  Marshﬁeld	  Clinic	  	  
3.  Mayo	  Clinic	  	  
4.  Northwestern	  University	  	  
5.  Group	  Health	  Coopera,ve-­‐UW	  	  
	  
AddiConal	  Sites	  in	  Phase	  II	  
1.  Geisinger	  
2.  Mount	  Sinai	  School	  of	  Medicine	  
3.  The	  eMERGE	  Coordina,ng	  Center	  at	  
Vanderbilt	  
	  
AddiConal	  Pediatric	  Sites	  in	  Phase	  II	  
1.  Childr n's	  Hospital	  of	  Philadelphia	  	  
2.  Cincinna,	  Children's	  Hospital	  Medical	  
Center	  &	  Boston	  Children's	  Hospital	  
	  
	  
	  
Clinical	  Validity?	  
	  
This	  is	  SO	  complex	  that	  the	  only	  solid	  
way	  forward	  is	  with	  a	  “networking	  of	  
science”	  model,	  i.e.	  online	  database	  
with	  genotype	  and	  phenotype	  
longitudinally	  tracked.	  
Genotype	  First,	  Phenotype	  Second	  
AND	  Longitudinally	  
•  Intellectual	  underpinnings	  of	  this	  seems	  to	  
emerge	  from	  the	  work	  of	  Evan	  Eichler	  &	  many	  
others,	  regarding	  CNVs	  and	  developmental	  
delay.	  
Phenotypic variability and genetic susceptibility
to genomic disorders
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The duplication architecture of the human genome predisposes our species to recurrent copy number
variation and disease. Emerging data suggest that this mechanism of mutation contributes to both
common and rare diseases. Two features regarding this form of mutation have emerged. First, common
structural polymorphisms create susceptible and protective chromosomal architectures. These structural
polymorphisms occur at varying frequencies in populations, leading to different susceptibility and ethnic
predilection. Second, a subset of rearrangements shows extreme variability in expressivity. We propose
that two types of genomic disorders may be distinguished: syndromic forms where the phenotypic features
are largely invariant and those where the same molecular lesion associates with a diverse set of diagnoses
including epilepsy, schizophrenia, autism, intellectual disability and congenital malformations. Copy number
variation analyses of patient genomes reveal that disease type and severity may be explained by the occur-
rence of additional rare events and their inheritance within families. We propose that the overall burden of
copy number variants creates differing sensitized backgrounds during development leading to different
thresholds and disease outcomes. We suggest that the accumulation of multiple high-penetrant alleles
of low frequency may serve as a more general model for complex genetic diseases, posing a significant
challenge for diagnostics and disease management.
INTRODUCTION
Genomic disorders were originally described as large deletions
and duplications that are highly penetrant, mostly de novo in
origin, and typically identified in affected individuals with intel-
lectual disability/multiple congenital malformations. Some
examples include Smith–Magenis syndrome (MIM: 182290),
DiGeorge/velocardiofacial syndrome (MIM: 188400, 192430)
andWilliams–Beuren syndrome (MIM: 194050). These classi-
cal genomic disorders have been well characterized in the past
two decades with genotype–phenotype correlation studies
implicating causative genes, mouse models recapitulating the
human clinical features, and standardized management proto-
cols and support groups established.
Application of higher definition molecular techniques,
including single-nucleotide polymorphism microarrays or
array comparative genomic hybridization (CGH), has allowed
genotyping of larger disease cohorts and controls. Two major
principles have emerged from these more recent studies: (i)
common copy number polymorphism predisposes certain
chromosomes to recurrent deletions and duplications and
(ii) association of the same recurrent genomic lesion with
apparently very diverse phenotypes. The latter has begun to
illuminate common neurodevelopmental pathways and
helps to explain the comorbidity of diverse neurological
manifestations within the same families. The distinction
between variability of expressivity and reduced penetrance
depending on the diagnosis has become an important consider-
ation for these rare mutational events. We will explore the
mechanisms, models and implications underlying these two
different aspects.
GENOMIC SUSCEPTIBILITY TO RECURRENT
DELETIONS AND DUPLICATIONS
Seminal work on Charcot–Marie–Tooth disease (1,2) and
hereditary neuropathy with liability to pressure palsies
(HNPP) (3) directly implicated low-copy repeats or segmental
duplications as substrates for unequal crossover or non-allelic
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VAAST	  shows	  that	  probabilis,c	  ranking	  
will	  be	  very	  useful	  going	  forward	  
•  But,	  VAAST	  is	  currently	  dependent	  on	  the	  variant	  lists	  
provided	  to	  it,	  as	  there	  is	  s,ll	  a	  heuris,c	  threshold	  with	  
input	  of	  variant	  data,	  i.e.	  no	  probabilis,c	  weigh,ng	  of	  
SNV	  or	  indel	  “true	  posi,ve	  likelihood”.	  
•  Therefore,	  need	  to	  op,mize	  variant-­‐calling	  to	  make	  
sure	  variants	  provided	  are	  correct.	  Plus,	  VAAST	  chokes	  
if	  background	  genomes	  are	  full	  of	  false	  posi,ves.	  
•  Thus,	  focused	  now	  on	  comprehensive	  comparison	  of	  
NGS	  variant-­‐calling	  on	  deep	  exome	  sequencing	  data	  
CLIA-­‐cer,ﬁed	  exomes	  and	  WGS	  
•  The	  CLIA-­‐cer,ﬁed	  pipelines	  a]empt	  to	  
minimize	  false	  posi,ves	  with	  increased	  
stringency,	  but	  this	  results	  in	  many	  no-­‐calls	  
and	  other	  areas	  of	  uncertainty,	  which	  should	  
be	  reported	  as	  No-­‐Call	  Regions.	  	  
•  BUT,	  this	  is	  ok,	  as	  minimizing	  false	  posi,ves	  is	  
very	  important	  in	  clinical	  medicine.	  	  
Op,mizing	  Variant	  Calling	  in	  Exomes	  
•  Agilent	  v2	  44	  MB	  exome	  kit	  
•  Illumina	  Hi-­‐Seq	  for	  sequencing.	  
•  Average	  coverage	  ~100-­‐150x.	  
•  Depth	  of	  sequencing	  of	  >80%	  of	  the	  target	  
region	  with	  >20	  reads	  or	  more	  per	  base	  pair.	  
•  Comparing	  various	  pipelines	  for	  alignment	  and	  
variant-­‐calling.	  
SNV	  venn	  plot 
Total	  	  SNP

Genomic Dark Matter: The reliability of short read
mapping illustrated by the Genome Mappability Score
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ABSTRACT
Motivation: Genome resequencing and short read mapping are two
of the primary tools of genomics and are used for many important
applications. The current state-of-the-art in mapping uses the quality
values and mapping quality scores to evaluate the reliability of the
mapping. These attributes, however, are assigned to individual
reads and don’t directly measure the problematic repeats across
the genome. Here we present the Genome Mappability Score
(GMS) as a novel measure of the complexity of resequencing a
genome. The GMS is a weighted probability that any read could be
unambiguously mapped to a given position, and thus measures the
overall composition of the genome itself.
Results: We have developed the Genome Mappability Analyzer
(GMA) to compute the GMS of every position in a genome. It
leverages the parallelism of cloud computing to analyze large
genomes, and enabled us to identify the 5-14% of the human,
mouse, fly, and yeast genomes that are difficult to analyze with short
reads. We examined the accuracy of the widely used BWA/SAMtools
polymorphism discovery pipeline in the context of the GMS, and
found discovery errors are dominated by false negatives, especially in
regions with poor GMS. These errors are fundamental to the mapping
process and cannot be overcome by increasing coverage. As such,
the GMS should be considered in every resequencing project to
pinpoint the dark matter of the genome, including of known clinically
relevant variations in these regions.
Availability: The source code and profiles of several model
organisms are available at http://gma-bio.sourceforge.net
Contact: hlee@cs.stonybrook.edu
1 INTRODUCTION
1.1 Background
DNA sequencing technology has dramatically improved in the past
decade so that today an individual human genome can be sequenced
for less than $10,000 and in less then two weeks (Drmanac et al.,
2010), compared to years of effort and hundreds of millions
of dollars for the first sequenced human genome (Stein, 2010).
This dramatic improvement has lead to an exponential growth in
sequencing, including several large projects to sequence thousands
of human genomes and exomes, such as the 1000 Genomes Project
∗to whom correspondence should be addressed
Consortium (2010) or International Cancer Genome Consortium
(2010). Other projects, such as ENCODE Project Consortium
(2004) and modENCODE Consortium (2010) are extensively using
resequencing and read mapping to discover novel genes and binding
sites.
The output of current DNA sequencing instruments consists of
billions of short, 25− 200 base pairs (bp) sequences of DNA called
reads, with an overall per base error rate around 1%-2% (Bentley
et al., 2008). In the case of whole genome resequencing, these
short reads will originate from random locations in the genome,
but nevertheless, entire genomes can be accurately studied by
oversampling the genome, and then aligning or ”mapping” each
read to the reference genome to computationally identify where it
originated. Once the entire collection of reads has been mapped,
variations in the sample can be identified by the pileup of reads that
significantly disagree from the reference genome (Fig. 1).
The leading short read mapping algorithms, including BWA (Li
and Durbin, 2009), Bowtie (Langmead et al., 2009), and SOAP (Li
et al., 2009b), all try to identify the best mapping position for each
read that minimizes the number of differences between the read and
the genome, i.e., the edit distance of the nucleotide strings, possibly
weighted by base quality value. This is made practical through
sophisticated indexing schemes, such as the Burrows-Wheeler
transform (Burrows and Wheeler, 1994), so that many billions of
reads can be efficiently mapped allowing for both sequencing errors
and true variations. The primary complication of short read mapping
is that a read may map equally well or nearly equally well to
multiple positions because of repetitive sequences in the genome.
Notably, nearly 50% of the human genome consists of repetitive
elements, including certain repeats that occur thousands of times
throughout (International Human Genome Sequencing Consortium,
2001).
For resequencing projects, the fraction of repetitive content
depends on read length and allowed error rate. At one extreme, all
single base reads would be repetitive, while chromosome length
reads would not be repetitive at all. Similarly, increasing the
allowed error rate increases the fraction of the genome that is
repetitive. The short read mapping algorithms use edit distance and
other read characteristics to compute a mapping quality score for
each mapped read (Li et al., 2008). The mapping quality score
estimates the probability that the assigned location is the correct
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ABSTRACT
M tivation: Genome resequencing and short read mapping are two
of the primary tools of genomics and are used for many important
applications. The current state-of-the-art in mapping uses the quality
values and mapping quality scores to evaluate the reliability of the
mapping. These attributes, however, are assigned to individual
reads and don’t directly measure the pro lematic repeats across
the genome. Here we present the Genome Mappability Score
(GMS) as a novel measure of the complexity of resequencing a
genome. The GMS is a weighted probability that any read could be
unambiguously mapped to a given position, and thus measures the
overall composition of the genome itself.
Results: We have developed the Genome Mappability Analyzer
(GMA) to compute the GMS of every position in a genome. It
leverages the parallelism of cloud computing to analyze large
genomes, and enabled us to identify the 5-14% of the hu n,
mouse, fly, and yeast genomes that are difficult to analyze with short
reads. We examined the accuracy of the widely used BWA/SAMtools
polymorphism discovery pipeline in the context of the GMS, and
found discovery errors are dominated by false negatives, especially in
regions with poor GMS. These errors are fundamental to the mapping
process and cannot be overcome by increasing coverage. As such,
the GMS should be considered in every resequencing project to
pinpoint the dark matter of the genome, including of known clinically
relevant variations in these regions.
Availability: The source code and profiles of several model
organisms are available at http://gma-bio.sourceforge.net
Contact: hlee@cs.stonybrook.edu
1 INTRODUCTION
1.1 Background
DNA sequencing technology has dramatically improved in the past
decade so that today an individual human genome can be sequenced
for less than $10,000 and in less then two weeks (Drmanac et al.,
2010), compared to years of effort and hundreds of millions
of dollars for the first sequenced human genome (Stein, 2010).
This dramatic improvement has lead to an exponential growth in
sequencing, including several large projects to sequence thousands
of human genomes and exomes, such as the 1000 Genomes Project
∗to whom correspondence should be addressed
Consortium (2010) or International Cancer Genome Consortium
(2010). Other projects, such as ENCODE Project Consortium
(2004) and modENCODE Consortium (2010) are extensively using
resequencing and read mapping to discover novel genes and binding
sites.
The output of current DNA sequencing instruments consists of
billions of short, 5− 200 base pairs (bp) sequences of DNA called
reads, with an overall per base error rate around 1%-2% (Bentley
et al., 2008). In the case of whole genome resequencing, these
short reads will originate from random locations in the genome,
but nev rtheless, entire genomes can be accurately studied by
oversampling the genome, and then aligning or ”mapping” each
read to the reference genome to computationally identify where it
originated. Once the entire collection of reads has been mapped,
variations in the sample can be identified by the pileup of reads that
significantly disagree from the reference genome (Fig. 1).
The leading short read mapping algorithms, including BWA (Li
and Durbin, 2009), Bowtie (Langmead et al., 2009), and SOAP (Li
et al., 2009b), all try to identify the best mapping position for each
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the genome, i.e., the edit distance of the nucleotide strings, possibly
weighted by base quality value. This is made practical through
sophisticated indexing schemes, such as the Burrows-Wheeler
transform (Burrows and Wheeler, 1994), so that many billions of
reads can be efficiently mapped allowing for both sequencing errors
and true variations. Th rimary complication of short read mapping
is that a read may map equally well or nearly equally well to
multiple positions because of repetitive sequences in the genome.
Notably, nearly 50% of the human genome consists of repetitive
elements, including certain repeats that occur thousands of times
throughout (International Human Genome Sequencing Consortium,
2001).
For resequencing projects, the fraction of repetitive content
depends on read length and allowed error rate. At one extreme, all
single base reads would be repetitive, while chromosome length
reads would not be repetitive at all. Similarly, increasing the
allowed error rate increases the fraction of the genome that is
repetitive. The short read mapping algorithms use edit distance and
other read characteristics to compute a mapping quality score for
each mapped read (Li et al., 2008). The mapping quality score
estimates the probability that the assigned location is the correct
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•  Genome	  Mappability	  Score	  (GMS)	  -­‐-­‐	  measure	  of	  the	  complexity	  of	  resequencing	  a	  
genome	  =	  a	  weighted	  probability	  that	  any	  read	  could	  be	  unambiguously	  mapped	  to	  a	  
given	  posi,on,	  and	  thus	  measures	  the	  overall	  composi,on	  of	  the	  genome	  itself.	  
•  Genome	  Mappability	  Analyzer	  (GMA)	  -­‐-­‐	  to	  comp te	  the	  GMS	  of	  every	  posi,on	  i 	  a	  
genome.	  Helps	  iden,fy	  the	  5-­‐14%	  of	  the	  human,	  mouse,	  ﬂy,	  and	  yeast	  genomes	  that	  
are	  diﬃcult	  to	  analyze	  with	  short	  reads.	  	  
•  With	  BWA/SAMtools	  polymorphism	  discovery	  pipeline,	  discovery	  errors	  are	  
dominated	  by	  false	  nega,ves,	  especially	  in	  regions	  with	  poor	  GMS.	  These	  errors	  are	  
fundament l	  to	  the	  mapping	  process	  and	  cannot	  be	  over ome	  by	  increasing	  
coverage.	  
	  	  
•  The	  GMS	  should	  be	  considered	  in	  every	  resequ nci g	  proje t	  to	  pinp in 	  the	  d rk	  
ma]er	  of	  the	  genome,	  including	  of	  known	  clini ally	  rel va t	  v ria,ons	  in	   e e	  
regi ns.	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Accurate whole-genome sequencing and
haplotyping from 10 to 20 human cells
Brock A. Peters1*, Bahram G. Kermani1*, Andrew B. Sparks1{, Oleg Alferov1, Peter Hong1, Andrei Alexeev1, Yuan Jiang1,
Fredrik Dahl1{, Y. Tom Tang1, Juergen Haas1, Kimberly Robasky2,3, Alexander Wait Zaranek2, Je-Hyuk Lee2,4,
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Recent advances in whole-genome sequencing have brought the vision of personal genomics and genomic medicine
closer to reality. However, currentmethods lack clinical accuracy and the ability to describe the context (haplotypes) in
which genome variants co-occur in a cost-effective manner. Here we describe a low-cost DNA sequencing and
haplotyping process, long fragment read (LFR) technology, which is similar to sequencing long single DNA molecules
without cloning or separation of metaphase chromosomes. In this study, ten LFR libraries were made using only
100 picograms of human DNA per sample. Up to 97% of the heterozygous single nucleotide variants were assembled
into long haplotype contigs. Removal of false positive single nucleotide variants not phased by multiple LFR haplotypes
resulted in a final genome error rate of 1 in 10megabases. Cost-effective and accurate genome sequencing and
haplotyping from 10–20 human cells, as demonstrated here, will enable comprehensive genetic studies and diverse
clinical applications.
The extraordinary advancements made in DNA sequencing tech-
nologies over the past few years have led to the elucidation of
,10,000 (refs 1–13) individual human genomes (303 or greater base
coverage) from different ethnicities and using different tech-
nologies2–13 and at a fraction of the cost10 of sequencing the original
human reference genome14,15. Although this is a monumental
achievement, the vast majority of these genomes have excluded a very
important element of human genetics. Individual human genomes are
diploid in nature, with half of the homologous chromosomes being
derived from each parent. The context in which variations occur on
each individual chromosome can have profound effects on the
expression and regulation of genes and other transcribed regions of
the genome16. Furthermore, determining whether two potentially
detrimental mutations occur within one or both alleles of a gene is
of paramount clinical importance.
Almost all recent human genome sequencing has been performed
on short read length (,200 base pairs (bp)), highly parallelized
systems starting with hundreds of nanograms of DNA. These tech-
nologies are excellent at generating large volumes of data quickly and
economically. Unfortunately, short reads, often paired with small
mate-gap sizes (500 bases–10 kilobases (kb)), eliminate most single
nucleotide polymorphism (SNP) phase information beyond a few
kilobases8. Population-based genotype data has been used to success-
fully assemble short-read data into long haplotype blocks3, but these
methods suffer from higher error rates and have difficulty phasing
rare variants17. Although using pedigree information18 or combining
it with population data provides further phasing power, no combina-
tion of these methods is able to resolve de novo mutations17.
At present, four personal genomes—J. Craig Venter19, a Gujarati
Indian (HapMap sample NA20847)11, and two Europeans (Max
Planck One13 and HapMap Sample NA12878 (ref. 20))—have been
sequenced and assembled as diploid. All have involved cloning long
DNA fragments in a process similar to that used for the construction
of the human reference genome14,15. Although these processes
generate long-phased contigs (N50 values (50% of the covered bases
are found within contigs longer than this number) of 350 kb19,
386 kb11 and 1megabase (Mb)13, and full-chromosome haplotypes
in combination with parental genotypes20) they require a large
amount of initial DNA, extensive library processing, and are currently
too expensive11 to use in a routine clinical environment. Furthermore,
several reports have recently demonstrated whole chromosome
haplotyping through direct isolation of metaphase chromosomes21–24.
These methods have yet to be used for whole-genome sequencing and
require preparation and isolation of whole metaphase chromosomes,
which can be challenging for some clinical samples. Here we introduce
long fragment read (LFR) technology, a process that enables genome
sequencing and haplotyping at a clinically relevant cost, quality and
scale.
LFR technology
The LFR approach can generate long-range phased variants because it
is conceptually similar to single-molecule sequencing of fragments
10–1,000 kb25 in length. This is achieved by the stochastic separation
of corresponding long parental DNA fragments into physically
distinct pools followed by subsequent fragmentation to generate
shorter sequencing templates (Fig. 1). The same principles are used
in aliquoting fosmid clones11,13. As the fraction of the genome in
each pool decreases to less than a haploid genome, the statistical
likelihood of having a corresponding fragment from both parental
chromosomes in the same pool markedly diminishes25. For example,
0.1 genome equivalents (300Mb) per well yields an approximately
10% chance that two fragments will overlap, and a 50% chance that
1Complete Genomics, Inc., 2071 Stierlin Court, Mountain View, California 94043, USA. 2Department of Genetics, Harvard Medical School, Cambridge, Massachusetts 02115, USA. 3Program in
Bioinformatics, Boston University, Boston, Massachusetts 02215, USA. 4Wyss Institute for Biologically Inspired Engineering, Harvard Medical School, Cambridge, Massachusetts 02115, USA. {Present
addresses: Aria Diagnostics, 5945 Optical Court, San Jose, California 95138, USA (A.B.S.); Halo Genomics, Dag Hammarskjolds vag 54A, 751 83 Uppsala, Sweden (F.D.).
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closer to reality. However, currentmethods lack clinical accuracy and the ability to describe the context (haplotypes) in
which genome variants co-occur in a cost-effective manner. Here we describe a low-cost DNA sequencing and
haplotyping process, long fragment read (LFR) technology, which is similar to sequencing long single DNA molecules
without cloning or separation of metaphase chromosomes. In this study, ten LFR libraries were made using only
100 picograms of human DNA per sample. Up to 97% of the heterozygous single nucleotide variants were assembled
into long haplotype contigs. Removal of false positive single nucleotide variants not phased by multiple LFR haplotypes
resulted in a final genome error rate of 1 in 10megabases. Cost-effective and accurate genome sequencing and
haplotyping from 10–20 human cells, as demonstrated here, will enable comprehensive genetic studies and diverse
clinical applications.
The extraordinary advancements made in DNA sequencing tech-
nologies over the past few years have led to the elucidation of
,10,000 (refs 1–13) individual human genomes (303 or greater base
coverage) from different ethnicities and using different tech-
nologies2–13 and at a fraction of the cost10 of sequencing the original
human reference genome14,15. Although this is a monumental
achievement, the vast majority of these genomes have excluded a very
important element of human genetics. Individual human genomes are
diploid in nature, with half of the homologous chromosomes being
derived from each parent. The context in which variations occur on
each individual chromosome can have profound effects on the
expression and regulation of genes and other transcribed regions of
the genome16. Furthermore, determining whether two potentially
detrimental mutations occur within one or both alleles of a gene is
of paramount clinical importance.
Almost all recent human genome sequencing has been performed
on short read length (,200 base pairs (bp)), highly parallelized
systems starting with hundreds of nanograms of DNA. These tech-
nologies are excellent at generating large volumes of data quickly and
economically. Unfortunately, short reads, often paired with small
mate-gap sizes (500 bases–10 kilobases (kb)), eliminate most single
nucleotide polymorphism (SNP) phase information beyond a few
kilobases8. Population-based genotype data has been used to success-
fully assemble short-read data into long haplotype blocks3, but these
methods suffer from higher error rates and have difficulty phasing
rare variants17. Although using pedigree information18 or combining
it with population data provides further phasing power, no combina-
tion of these methods is able to resolve de novo mutations17.
At present, four personal genomes—J. Craig Venter19, a Gujarati
Indian (HapMap sample NA20847)11, and two Europeans (Max
Planck One13 and HapMap Sample NA12878 (ref. 20))—have been
sequenced and assembled as diploid. All have involved cloning long
DNA fragments in a process similar to that used for the construction
of the human reference genome14,15. Although these processes
generate long-phased contigs (N50 values (50% of the covered bases
are found within contigs longer than this number) of 350 kb19,
386 kb11 and 1megabase (Mb)13, and full-chromosome haplotypes
in combination with parental genotypes20) they require a large
amount of initial DNA, extensive library processing, and are currently
too expensive11 to use in a routine clinical environment. Furthermore,
several reports have recently demonstrated whole chromosome
haplotyping through direct isolation of metaphase chromosomes21–24.
These methods have yet to be used for whole-genome sequencing and
require preparation and isolation of whole metaphase chromosomes,
which can be challenging for some clinical samples. Here we introduce
long fragment read (LFR) technology, a process that enables genome
sequencing and haplotyping at a clinically relevant cost, quality and
scale.
LFR technology
The LFR approach can generate long-range phased variants because it
is conceptually similar to single-molecule sequencing of fragments
10–1,000 kb25 in length. This is achieved by the stochastic separation
of corresponding long parental DNA fragments into physically
distinct pools followed by subsequent fragmentation to generate
shorter sequencing templates (Fig. 1). The same principles are used
in aliquoting fosmid clones11,13. As the fraction of the genome in
each pool decreases to less than a haploid genome, the statistical
likelihood of having a corresponding fragment from both parental
chromosomes in the same pool markedly diminishes25. For example,
0.1 genome equivalents (300Mb) per well yields an approximately
10% chance that two fragments will overlap, and a 50% chance that
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“Substan,al	  error	  rates	  (1	  single	  nucleo,de	  variants	  (SNV)	  in	  100–1,000	  called	  
kilobases)	  are	  a	  common	  a]ribute	  of	  all	  curr nt	  massively	  
parallelized	  sequencing	  technologies2–10,12.	  Th se	  rates	   re	  probably	  too	  high	  
for	  diagnos,c	  use	  and	  complicate	  many	  studies	  searching	  for	  
new	  muta,ons.”	  
Much	  Higher	  Accuracy	  with	  LFR	  data	  
“To	  test	  LFR	  reproducibility	  we	  compared	  
haplotype	  data	  between	  the	  two	  NA19240	  
replicate	  libraries.	  In	  general,	  the	  libraries	  were	  
very	  concordant,	  with	  only	  64	  diﬀerences	  per	  
library	  in	  2.2	  million	  heterozygous	  SNPs	  phased	  
by	  both	  libraries	  or	  1	  of	  this	  error	  type	  in	  44	  
Mb.”	  
	  
those fragments will be derived from separate parental chromosomes.
The end result is a roughly 5% overall chance that a particular well will
be uninformative for a given fragment. Likewise, the more individual
pools interrogated the greater the number of times a fragment
from the maternal and paternal homologues will be analysed in
separate pools. The current version of LFR uses a 384-well plate
with 10–20% of a haploid genome in each well, yielding a theoretical
19–383 physical coverage of both the maternal and paternal alleles of
each fragment (see Supplementary Materials and Supplementary
Table 1 for an explanation of how this amount of material was
selected). This high initial DNA redundancy of 19–383 versus
recently described strategies using fosmid pools of 33 (ref. 11) or
63 (ref. 13) ensures complete genome coverage and higher variant
calling and phasing accuracy.
To prepare LFR libraries in a high-throughput manner we
developed an automated process that performs all LFR-specific steps
in the same 384-well plate. First, a highly uniform amplification using
a modified, W29 polymerase-based, multiple displacement amplifica-
tion (MDA)26 is performed to replicate each fragment about 10,000
times. Next, through a process of five enzymatic steps within each
well, without intervening purification steps, DNA is fragmented and
ligated with barcode adapters. In brief, long DNA molecules are
processed to blunt-ended 300–1,500-bp fragments through the new
process of controlled random enzymatic fragmenting (Supplementary
Methods and Supplementary Figs 2 and 3). Unique 10-base Reed–
Solomon27 error-correcting barcode adapters (Supplementary Fig. 4)
are then ligated to fragmentedDNA in eachwell using a high yield, low
chimaera formation protocol10. Lastly, all 384 wells are combined and
an unsaturated PCR using primers common to the ligated adapters is
used to generate sufficient template for massively parallel short-read
sequencing platforms (see Supplementary Methods). The addition of
the LFR pre-processing steps to the standard library process adds at
present about US$100 to the reagent cost of our genome sequencing
(Supplementary Table 2).
LFR libraries from 10 cells or 100pg of isolated DNA
As a demonstration of the power of LFR to determine an accurate
diploid genome sequence, we generated three libraries of Yoruban
female HapMap sample NA19240, six libraries from European
HapMap pedigree 1463 (Supplementary Fig. 5), and a single library
from Personal Genome Project sample NA20431. Pedigree 1463 and
NA19240 have been extensively studied in the HapMap Project28,29,
the 1,000 Genomes Project30 and our own efforts (http://www.
completegenomics.com/sequence-data/download-data/). As a result,
highly accurate haplotype information can be generated for these
samples based on the redundant sequence data from familial samples.
One NA19240 LFR library was made from 10 cells of the correspond-
ing immortalized B-cell line, all other libraries were made from an
estimated 100–130 pg (equivalent to 15–20 cells) of denatured high
molecularmass genomicDNA (Supplementary Fig. 6 and Supplemen-
tary Methods). Libraries were analysed using the sequencing platform
of Complete Genomics10. Thirty-five-base mate-paired reads were
mapped to the reference genome using a custom alignment
algorithm10,31, yielding on average more than 250 gigabases (Gb) of
mapped data with an average genomic coverage of.803 (Table 1 and
Supplementary Table 3). Analysis of the mapped LFR data shows two
distinct characteristics attributable to MDA: slight underrepresenta-
tion of GC-rich sequences (Supplementary Fig. 7) and an increase in
chimaeric sequences (Supplementary Table 3). In addition, coverage
normalized across 100-kb windows was more variable (Supplemen-
tary Fig. 8). Nevertheless, almost all genomic regions were covered
with sufficient reads (five or more) demonstrating that 10,000-fold
MDA amplification by our optimized protocol can be used for com-
prehensive genome sequencing. Barcodes were used to groupmapped
reads based on their physical well location within each library, result-
ing in sparse regions of coverage interspersed between long spanswith
almost no read coverage (Supplementary Fig. 9). Each of these discrete
regions of coverage represents a physical DNA fragment. On average,
each well contained 10–20% of a haploid genome (300–600Mb), in
fragments ranging from10 kb tomore than 300 kb in lengthwithN50s
of ,60 kb (Table 1). Initial fragment coverage was very uniform
between chromosomes (Supplementary Fig. 10). As estimated from
all detected fragments, the total amounts of DNA used to make the
two NA19240 libraries from extracted DNA were ,62 pg and 84 pg
(equivalent to 9.4 and 12.7 cells, respectively). This is less than the
expected 100–130 pg, indicating some lost or undetected DNA or
imprecision in DNA quantification. Notably, the 10-cell library
seemed to be made from ,90 pg (13.6 cells) of DNA, probably due
to some of the cells being in S phase during isolation (Table 1).
LFR haplotyping results
To ensure complete representation of the genome we maximized the
input of DNA fragments for a given read coverage and number of
aliquots (Supplementary Materials and Supplementary Table 1).
Unlike other experimental approaches11,13,20, this resulted in low-
coverage read data (,23) for each fragment in each of the,40 wells
a fragment is found in. This type of data is not useful for defining
haplotypes for each initial fragment and required the development of
a new phasing algorithm that statistically combines reads from related
fragments found in separate aliquots (Supplementary Methods and
Fig. 2). Application of our algorithm to the LFR libraries resulted in
the placement of on average 92% of the phasable heterozygous SNPs
into long contigs with N50s of,1Mb and,500 kb for the NA19240
and European samples, respectively (Table1 and Supplementary
120 pg
HMM
genomic
DNA
C
A
T
T
AG
T
C A T T A
G
G
G
G
C
C
C
C
G
G
G T
C
C
G
G Parent 1
Parent 2
Parent 1 Parent 2
Barcode
adapters
Wells
1
2
384
(iv)
(ii)
(i)
(v)
. . . . . . . 
1
2
384
(iii)
. . . . . . . 
Figure 1 | The LFR technology. An overview of the LFR technology and
controlled random enzymatic fragmenting is shown. (i) First, 100–130 pg of
high molecular mass (HMM) DNA is physically separated into 384 distinct
wells; (ii) through several steps, all within the same well without intervening
purifications, the genomic DNA is amplified, fragmented and ligated to unique
barcode adapters; (iii) all 384 wells are combined, purified and introduced into
the sequencing platform of Complete Genomics10; (iv) mate-paired reads are
mapped to the genome using a custom alignment program and barcode
sequences are used to group tags into haplotype contigs; and (v) the final result
is a diploid genome sequence.
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Whole	  Genome	  Sequencing	  in	  a	  centralized	  
facility	  is	  a	  “Disrup,ve	  Technology”	  	  
•  This	  is	  only	  true	  with	  economy	  of	  scale,	  done	  
well	  and	  with	  CLIA	  cer,ﬁca,on.	  	  
•  It	  can	  and	  should	  replace	  single	  gene	  
diagnos,c	  tests	  for	  pa,ents	  presen,ng	  with	  
severe	  gene,c	  illnesses,	  which	  can	  themselves	  
each	  cost	  $3000!	  
•  	  Some,mes,	  physicians	  spend	  
$30,000-­‐100,000	  on	  diagnos,c	  odysseys	  with	  
numerous	  single	  gene	  tests.	  
Systemic	  Barriers	  
•  Some,mes	  just	  simple	  lack	  of	  communica,on	  
between	  researchers	  and	  the	  physicians	  and	  
gene,c	  counselors.	  
•  We	  only	  have	  1500	  medical	  gene,cists	  and	  2000	  
cer,ﬁed	  gene,c	  counselors	  for	  310	  million	  
people	  in	  America!	  	  
•  Insurance	  will	  o}en	  deny	  coverage	  of	  gene,c	  
tes,ng.	  
Systemic	  Barriers	  cont….	  
•  Physicians	  and	  health	  care	  system	  woefully	  
uneducated	  regarding	  gene,cs.	  
•  Most	  current	  sequencing	  (exomes	  and	  whole	  
genomes)	  being	  sequenced	  in	  random	  
laboratories	  with	  no	  clinical	  standards	  in	  
place.	  
Quote	  from	  Cliﬀord	  Reid	  at	  Complete	  
Genomics	  
•  “We	  have	  higher	  quality.	  But	  in	  the	  research	  
market	  that	  doesn’t	  ma]er	  very	  much.	  
Researchers	  can	  work	  with	  lower	  quality	  data.	  
That’s	  really	  been	  a	  startling	  revela,on	  to	  us	  
that	  despite	  the	  community	  saying	  quality	  is	  
everything,	  quality	  really	  isn’t	  everything.”	  
-­‐-­‐-­‐	  h]p://www.forbes.com/sites/ma]hewherper/
2012/07/13/can-­‐complete-­‐genomics-­‐escape-­‐the-­‐valley-­‐
of-­‐death/	  
•  “The	  ability	  to	  noninvasively	  sequence	  a	  fetal	  
genome	  to	  high	  accuracy	  and	  completeness	  
will	  undoubtedly	  have	  profound	  implica,ons	  
for	  the	  future	  of	  prenatal	  gene,c	  diagnos,cs.”	  
•  Yes,	  but	  this	  is	  NOT	  that	  study!	  
GENOMICS
Noninvasive Whole-Genome Sequencing of a
Human Fetus
Jacob O. Kitzman,1* Matthew W. Snyder,1 Mario Ventura,1,2 Alexandra P. Lewis,1 Ruolan Qiu,1
LaVone E. Simmons,3 Hilary S. Gammill,3,4 Craig E. Rubens,5,6 Donna A. Santillan,7
Jeffrey C. Murray,8 Holly K. Tabor,5,9 Michael J. Bamshad,1,5 Evan E. Eichler,1,10 Jay Shendure1*
Analysis of cell-free fetal DNA in maternal plasma holds promise for the development of noninvasive prenatal
genetic diagnostics. Previous studies have been restricted to detection of fetal trisomies, to specific paternally
inherited mutations, or to genotyping common polymorphisms using material obtained invasively, for example,
through chorionic villus sampling. Here, we combine genome sequencing of two parents, genome-wide maternal
haplotyping, and deep sequencing of mater al plasm DNA to noninvasively det rmine the genome sequence
of a human fetus at 18.5 weeks of gestation. Inheritance was predicted at 2.8 × 106 parental heterozygous sites
with 98.1% accuracy. Furthermore, 39 of 44 de novo point mutations in the fetal genome were detected, albeit
with limited specificity. Subsampling these data and analyzing a second family trio by the same approach in-
dicate that parental haplotype blocks of ~300 kilo–base pairs combined with shallow sequencing of maternal
plasma DNA is sufficient to substantially determine the inherited complement of a fetal genome. However,
ultradeep sequencing of maternal plasma DNA is necessary for the practical detection of fetal de novo mutations
genome-wide. Although technical and analytical challenges remain, we anticipate that noninvasive analysis of
inherited variation and de novo mutations in fetal genomes will facilitate prenatal diagnosis of both recessive
and dominant Mendelian disorders.
INTRODUCTION
On average, ~13% of cell-free DNA isolated frommaternal plasma dur-
ing pregnancy is fetal in origin (1). The concentration of cell-free fetal
DNA in the maternal circulation varies between individuals, increases
during gestation, and is rapidly cleared postpartum (2, 3). Despite this
variability, cell-free fetal DNA has been successfully targeted for non-
invasive prenatal diagnosis including for development of targeted assays
for single-gene disorders (4). More recently, several groups have dem-
onstrated that shotgun,massively parallel sequencing of cell-freeDNA
from maternal plasma is a robust approach for noninvasively diag-
nosing fetal aneuploidies such as trisomy 21 (5, 6).
Ideally, it should be possible to noninvasively predict the whole-
genome sequence of a fetus to high accuracy and completeness, poten-
tially enabling the comprehensive prenatal diagnosis of Mendelian
disorders and obviating the need for invasive prenatal diagnostic proce-
dures such as chorionic villus sampling with their attendant risks. How-
ever, several key technical obstacles must be overcome for this goal to
be achieved using cell-freeDNA frommaternal plasma. First, the sparse
representationof fetal-derived sequences poses the challenge of detecting
low-frequency alleles inherited from the paternal genomeaswell as those
arising from de novomutations in the fetal genome. Second,maternal
DNApredominates in themother’s plasma,making it difficult to assess
maternally inherited variation at individual sites in the fetal genome.
Recently, Lo et al. showed that fetal-derived DNA is distributed
sufficiently evenly in maternal plasma to support the inference of fetal
genotypes, and furthermore, they demonstrated how knowledge of
parental haplotypes could be leveraged to this end (7). However, their
study was limited in several ways. First, the proposedmethod depended
on the availability of parental haplotypes, but at the time of their work,
no technologies existed to measure these experimentally on a genome-
wide scale. Therefore, an invasive procedure, chorionic villus sampling,
was used to obtain placental material for fetal genotyping. Second, pa-
rental genotypes and fetal genotypes obtained invasively were used to
infer parental haplotypes. These haplotypes were then used in combi-
nation with the sequencing of DNA from maternal plasma to predict
the fetal genotypes. Although necessitated by the lack of genome-wide
haplotyping methods, the circularity of these inferences makes it diffi-
cult to assess how well the method would perform in practice. Third,
their analysis was restricted to several hundred thousand parentally het-
erozygous sites of common single-nucleotide polymorphisms (SNPs)
represented on a commercial genotyping array. These common SNPs
are only a small fraction of the severalmillion heterozygous sites present
in each parental genome and include few of the rare variants that pre-
dominantly underlie Mendelian disorders (8). Fourth, Lo et al. did not
ascertain de novo mutations in the fetal genome. Because de novo mu-
tations underlie a substantial fraction of dominant genetic disorders,
their detection is critical for comprehensive prenatal genetic diagnostics.
Therefore, although the Lo et al. study demonstrated the first successful
construction of a genetic map of a fetus, it required an invasive proce-
dure and did not attempt to determine the whole-genome sequence
of the fetus. We and others recently demonstrated methods for exper-
imentally determining haplotypes for both rare and common variation
1Department of Genome Sciences, University of Washington, Seattle, WA 98195, USA.
2Department of Biology, University of Bari, Bari 70126, Italy. 3Department of Obstetrics
and Gynecology, University of Washington, Seattle, WA 98195, USA. 4Division of Clinical
Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. 5De-
partment of Pediatrics, University of Washington School of Medicine, Seattle, WA 98195,
USA. 6Global Alliance to Prevent Prematurity and Stillbirth, an initiative of Seattle
Children’s, Seattle, WA 98101, USA. 7Department of Obstetrics and Gynecology, Univer-
sity of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA. 8Department of Pediatrics,
University of Iowa, Iowa City, IA 52242, USA. 9Treuman Katz Center for Pediatric
Bioethics, Seattle Children’s Research Institute, Seattle, WA 98101, USA. 10Howard
Hughes Medical Institute, Seattle, WA 98195, USA.
*To whom correspondence should be addressed. E-mail: shendure@uw.edu (J.S.);
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Actual	  Data	  
•  “we	  found	  2.5	  ×	  107	  candidate	  de	  novo	  sites,	  
including	  39	  of	  the	  44	  true	  de	  novo	  sites.	  At	  
baseline,	  this	  corresponds	  to	  sensi,vity	  of	  88.6%	  
with	  a	  signal-­‐	  to-­‐noise	  ra,o	  of	  1-­‐to-­‐640,000”	  
•  With	  other	  ﬁlters,	  they	  reduce	  number	  of	  “total	  
posi,ves”	  to	  3884,	  of	  which	  17	  are	  true	  posi,ves,	  
from	  total	  known	  true	  posi,ves	  of	  44),	  so	  
sensi,vity=	  38.6%.	  
•  This	  is	  nowhere	  near	  accurate,	  or	  anything	  
remotely	  close	  to	  a	  clinical	  grade	  test!	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Understanding the spectrum of allelic variation in human genes and 
revealing the demographic and evolutionary forces that shape this varia-
tion within and among populations is a major aim of human genetics 
research. Such information is critical for defining the architecture of 
common diseases, identifying functionally important variation, and ulti-
mately facilitating the interpretation of personalized disease risk profiles 
(1–3). To date, surveys of human variation have been dominated by 
studies of single nucleotide polymorphisms (SNPs) genotyped using 
high-density arrays composed of common variants (4–6). While these 
projects have substantially improved our knowledge of common allelic 
variation and enabled genome-wide association studies (GWAS), they 
have been generally uninformative about the population genetics charac-
teristics of rare variants, defined here as a minor allele frequency (MAF) 
of less than 0.5%. 
Rare genetic variants are predicted to vastly outnumber common 
variants in the human genome (7, 8). By capturing and sequencing all 
protein-coding exons (i.e., the exome, which comprises ~1-2% of the 
human genome), exome sequencing is a powerful approach for discover-
ing rare variation and has facilitated 
the genetic dissection of unsolved 
Mendelian disorders and studying 
human evolutionary history (9–14). 
Rare and low frequency (MAF be-
tween 0.5%-1%) variants have been 
hypothesized to explain a substantial 
fraction of the heritability of common, 
complex diseases (15). Since common 
variants explain only a modest fraction 
of the heritability of most traits (16, 
17), NHLBI recently sponsored the 
multicenter Exome Sequencing Project 
(ESP), to identify novel genes and 
molecular mechanisms underlying 
complex heart, lung, and blood disor-
ders by sequencing the exomes of a 
large number of individuals measured 
for phenotypic traits of substantial 
public health significance (e.g., early-
onset myocardial infarction, stroke, 
body mass index). 
Data generation and variant dis-
covery. A total of 63.4 terabases of 
DNA sequence was generated at two 
centers with three complimentary defi-
nitions of the exome target and two 
different capture technologies (18). We 
sequenced samples from 14 different 
cohorts in the ESP to an average medi-
an depth of 111x (range 23x – 474x). 
We found no evidence of cohort- 
and/or phenotype specific effects, or 
other systematic biases, in the analysis 
of the filtered SNV data (18; Figs. S1-
S7). Exomes from related individuals 
were excluded from further analysis 
(18; Fig. S8) resulting in a dataset of 
2,440 exomes. We inferred genetic 
ancestry using a clustering approach 
(18), and focused the remaining anal-
yses on the inferred 1,351 EA and 
1,088 AA individuals. We subjected 
the 563,698 variants in the intersection 
of all three capture targets to standard 
quality control filters (18) resulting in a final data set of 503,481 single 
nucleotide variants (SNVs) identified in 15,585 genes and 22.38 Mb of 
targeted sequence per individual. We assessed data quality and error 
rates using complementary strategies (18). Approximately 98% 
(941/961) of all variant sites that were experimentally tested were con-
firmed, including 98% (234/238) of singletons, 98% (678/693) of non-
singleton SNV sites with a MAF < 10%, and 97% (29/30) of SNV sites 
ZLWKD0$) 
The vast majority of coding variation is rare and novel. We ob-
served a total of 503,481 SNVs and 117 fixed, non-reference sites, of 
which 325,843 and 268,903 were found in AA and EA, respectively (18; 
Fig. S9A). Excluding singletons, ~58% of SNVs were population-
specific (93,278 and 32,552 variants were uniquely observed in AA, or 
EA, respectively), and the vast majority of these variants were rare (18; 
Fig. S9B). Most SNVs (292,125 or 58%) were nonsynonymous includ-
ing 285,960 missense variants and 6,165 nonsense variants (18; Fig. 
S9C). Synonymous variants accounted for 38% (188,975) of the total 
SNVs (18; Fig. S9C), with the remaining 4% of SNVs (22,381) located 
Evolution and Functional Impact of 
Rare Coding Variation from Deep 
Sequencing of Human Exomes 
Jacob A. Tennessen,1* Abigail W. Bigham,2*† Timothy D. O’Connor,1* Wenqing 
Fu,1 Eimear E. Kenny,3 Simon Gravel,3 Sean McGee,1 Ron Do,4,5 Xiaoming Liu,6 
Goo Jun,7 Hyun Min Kang,7 Daniel Jordan,8 Suzanne M. Leal,9 Stacey Gabriel,4 
Mark J. Rieder,1 Goncalo Abecasis,7 David Altshuler,4 Deborah A. Nickerson,1 
Eric Boerwinkle,6,10 Shamil Sunyaev,4,8 Carlos D. Bustamante,3 Michael J. 
Bamshad,1,2‡ Joshua M. Akey,1‡ Broad GO, Seattle GO, on behalf of the NHLBI 
Exome Sequencing Project 
1Department of Genome Sciences, University of Washington, Seattle, Washington, USA. 2Department of 
Pediatrics, University of Washington, Seattle, Washington, USA. 3Department of Genetics, Stanford 
University, Stanford, California, USA. 4Broad Institute of MIT and Harvard, Cambridge, Massachusetts, 
USA. 5The Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts, 
USA. 6Human Genetics Center, University of Texas Health Sciences Center at Houston, Houston, Texas, 
USA. 7Department of Biostatistics, University of Michigan, Ann Arbor, Michigan, USA. 8Division of Genetics, 
Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA. 9Department of Molecular and 
Human Genetics, Baylor College of Medicine, Houston, TX, USA. 10Human Genome Sequencing Center, 
Baylor College of Medicine, Houston, Texas, USA. 
*These authors contributed equally to this work. 
†Present address: Department of Anthropology, University of Michigan, Ann Arbor, MI, USA. 
‡To whom correspondence should be addressed. E-mail: akeyj@uw.edu (J.M.A.); 
mbamshad@u.washington.edu (M.J.B.) 
As a first step toward understanding how rare variants contribute to risk for 
complex diseases, we sequenced 15,585 human protein-coding genes to an average 
median depth of 111x in 2,440 individuals of European (n=1,351) and African 
(n=1,088) ancestry. We identified >500,000 single nucleotide variants (SNVs), the 
majority of which were rare (86% with a minor allele frequency < 0.5%), novel (82%), 
and population-specific (82%). On average, 2.3% of the 13,595 SNVs each person 
carries were predicted to impact protein function of ~313 genes per genome, and 
~95.7% of SNVs predicted to be functionally important were rare. This excess of rare 
functional variants is due to the combined effects of explosive, recent accelerated 
population growth and weak purifying selection. Furthermore, we show that large 
sample sizes will be required to associate rare variants with complex traits. 
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A RT I C L E S
Crohn’s disease and ulcerative colitis are classified as chronic, idi-
opathic inflammatory bowel diseases (IBDs) of the gastrointestinal 
tract with unknown etiology (MIM266600). Crohn’s disease occurs 
in about 100–150 per 100,000 individuals of European a cestry1. 
Generally, the disease affects the ileum and colon, but it can affect any 
region of the gut. Ulcerative colitis has similar population prevalence, 
and although it has some similarities to Crohn’s disease in clinical 
manifestation, the location of inflammation is limited to the colonic 
mucosa. Strong familial aggregation has been observed in twin studies 
of Crohn’s disease and ulcerative colitis2,3. Recent population-based 
sibling risk is 26-fold greater for Crohn’s diseas  and 9-fold greater for 
ulcerative colitis2, and overall Crohn’s disease and ulcerative colitis 
concordance rates in nonselected twin studies are 30% and 15%, 
respectively, among monozygotic twins compared with 4% for 
Crohn’s disease or ulcerative colitis among dizygotic twins3. Like most 
complex diseases, Crohn’s disease and lcerative colitis result from 
a combination of genetic and nongenetic risk factors, and each 
individual factor probably has a modest effect on disease risk4.
Deep resequencing of GWAS loci identifies independent 
rare variants associated with inflammatory bowel disease
Manuel A Rivas1–3, Mélissa Beaudoin4,23, Agnes Gardet5,23, Christine Stevens2,23, Yashoda Sharma6,  
Clarence K Zhang6, Gabrielle Boucher4, Stephan Ripke1,2, David Ellinghaus7, Noel Burtt2, Tim Fennell2,  
Andrew Kirby1,2, Anna Latiano8, Philippe Goyette4, Todd Green2, Jonas Halfvarson9, Talin Haritunians10,  
Joshua M Korn2, Finny Kuruvilla2,11, Caroline Lagacé4, Benjamin Neale1,2, Ken Sin Lo4, Phil Schumm12,  
Leif Törkvist13, National Institute of Diabetes and Digestive Kidney Diseases Inflammatory Bowel Disease 
Genetics Consortium (NIDDK IBDGC)14, United Kingdom Inflammatory Bowel Disease Genetics Consortium14, 
International Inflammatory Bowel Disease Genetics Consortium14, Marla C Dubinsky15, Steven R Brant16,17, 
Mark S Silverberg18, Richard H Duerr19,20, David Altshuler1,2, Stacey Gabriel2, Guillaume Lettre4, Andre Franke7, 
Mauro D’Amato21, Dermot P B McGovern10,22, Judy H Cho6, John D Rioux4, Ramnik J Xavier1,2,5 & Mark J Daly1,2
More than 1,000 susceptibility loci have been identified through genome-wide association studies (GWAS) of common variants; 
however, the specific genes and full allelic spectrum of causal variants underlying these findings have not yet been defined. Here 
we used pooled next-generation sequencing to study 56 genes from regions associated with Crohn’s disease in 350 cases and 350 
controls. Through follow-up genotyping of 70 rare and low-frequency protein-altering variants in nine independent case-control 
series (16,054 Crohn’s disease cases, 12,153 ulcerative colitis cases and 17,575 healthy controls), we identified four additional 
independent risk factors in NOD2, two additional protective variants in IL23R, a highly significant associa i n with a protective 
splice varia t in CARD9 (P < 1 × 10−16, odds ratio y 0.29) and additional associations with coding variants in IL18RAP, CUL2, 
C1orf106, PTPN22 and MUC19. We extend the results of successful GWAS by identifying new, rare and probably functional 
variants that could aid functional experiments and predictive models.
1Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts, USA. 2Broad Institute of Harvard and MIT, Cambridge, 
Massachusetts, USA. 3Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK. 4Université de Montréal and Research Centre, Montreal Heart 
Institute, Mo treal, Quebec, Can da. 5Gastrointestinal Unit, Center for the Study of the Inflammatory Bowel Disease and Center for Computational and Integrative 
Biology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. 6Yale School of Medicine, New Haven, Connecticut, USA. 7Institute 
of Clinical Molecular Biology, Kiel, Germany. 8Unit of Gastroenterology, Istituto Di Ricovero e Cura a Carattere Scientifico, Casa Sollievo della Sofferenza Hospital,  
San Giovanni Rotondo, Italy. 9Örebro University Hospital, Department of Medicine and School of Health and Medical Sc ences, Örebro Univ rsity, Örebro, Sweden. 
10The Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA. 11Clarus Ventures, Cambridge, Massachusetts, USA. 12Department 
of Health Studies, University of Chicago, Chicago, Illinois, USA. 13Karolinska Institutet, Department of Clinical Science Intervention and Technology, Stockholm, 
Sweden. 14A full list of consortium members is provided in the Supplementary Note. 15The Pediatric Inflammatory Bowel Disease Center, Cedars-Sinai Medical  
Center, Los Angeles, California, U A. 16Meyerhoff Inflammatory B w l Disease Center, Department of Medicine, School of Medicine, Johns Hopkins University, 
Baltimore, Maryland, USA. 17Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA. 18Mount Sinai 
Hospital Inflammatory Bowel Disease Group, University of Toronto, Toronto, Ontario, Canada. 19Division of Gastroenterology, Hepatology and Nutrition, Department 
of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. 20Department of Human Genetics, Graduate School of Public Health, 
University of Pittsburgh, Pittsburgh, Pennsylvania, USA. 21Karolinska Institutet, Department of Bioscience  and Nutrition, Stockholm, Sweden. 22Inflammatory  
Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA. 23These authors contributed equally to this work. 
Correspondence should be addressed to M.J.D. (mjdaly@atgu.mgh.harvard.edu) or M.A.R. (rivas@broadinstitute.org).
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High Frequencies of De Novo CNVs
in Bipolar Disorder and Schizophrenia
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SUMMARY
While it is known that rare copy-number variants
(CNVs) contribute to risk for some neuropsyc iatric
disorders, the role of CNVs in bipolar disorder is
unclear. Here, we reasoned that a contribution of
CNVs to mood disorders might be most evident for
de novo mutations. We performed a genome-wide
an lysis of de novo CNVs in a cohort of 788 rios.
Diagnoses of offspring included bipolar disorder
(n = 185), schizophre ia ( = 177), and healthy
controls (n = 426). Frequencies of de novo CNVs
were significantly higher in bipolar disorder as com-
pared with controls (OR = 4.8 [1.4,16.0], p = 0.009).
De novo CNVs were particularly enriched among
cases with an age at onset younger than 18 (OR =
6.3 [1.7,22.6], p = 0.006). We also confirmed a signifi-
cant enrichment of de novo CNVs in schizophrenia
(OR = 5.0 [1.5,16.8], p = 0.007). Our results suggest
that rare spontaneous mutations are an important
contributor to risk for bipolar diso der and other
major neurop ychiatric diseases.
INTRODUCTION
Bipolar disorder (BD, also known s a ic-depressive illness) is
a severe ood disord r onsisti g of episodes of mania and
epression. The lifetime prevalence of bipolar disorder in the
gen ral population is !1% and the illness i associated with
consid rable morbidity and a high lif time isk of suicide (Meri-
kangas et al., 2011).
Genes play an important r le in risk for BD. Th rate of concor-
dance formonozygotic twins is 40%, comparedwith a 5% rate in
dizygotic twins (Kendler et al., 1995; Kieseppa¨ et al., 2004;
McGuffin et al., 2003), and risk among the first-degree relatives
of individuals with BD is ten-fold greater than risk among the
general population (Barnett and Smoller, 2009). However, as
with other psychiatric disorders, the genetics of BD is complex,
Neuron 72, 951–963, December 22, 2011 ª2011 Elsevier Inc. 951
Rare	  Variants	  –	  CNVs,	  SNVs,	  indels,	  etc…	  in	  Rare	  AND	  Common	  diseases	  
“Superpower”	  muta,ons???	  
LRP5	  muta,on	  
D111Y,	  G171R,	  A214T,	  A214V,	  A242T,	  and	  
T253I	  	  	  
Myosta,n	  muta,on	  	  
	  Exon	  2	  allele	  	  P198A	  
**Thanks	  to	  George	  Church	  for	  discussions	  on	  this.	  
Another	  example:	  Liam	  Hoekstra,	  known	  as	  the	  world's	  strongest	  
toddler	  at	  age	  3,	  has	  a	  condi,on	  called	  myosta,n-­‐related	  muscle	  
hypertrophy	  which	  results	  in	  increased	  muscle	  mass	  and	  reduced	  body	  
fat.	  Myosta,n-­‐related	  muscle	  hypertrophy,	  or	  muscle	  enlargement,	  is	  
an	  extremely	  rare	  gene,c	  condi,on.	  –	  How	  rare???	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hours after birth, and the infant was admitted to
the neonatal ward for assessment. He appeared ex-
traordinarily muscular, with protruding muscles
in his thighs (Fig. 1A) and upper arms. With the
exception of increased tendon reflexes, the physi-
cal examination was normal. Hypoglycemia and
increased levels of testosterone and insulin-like
growth factor I were excluded. Muscular hypertro-
phy was verified by ultrasonography when the in-
fant was six days of age (Fig. 1B and 1C). Doppler
echocardiography and electrocardiography per-
formed soon after birth and every six months there-
after were consistently normal. At 4.3 years of age
(body-surface area, 0.78 m
 
2
 
), the child had a pulse
rate of 95 beats per minute, a left ventricular ejection
fraction of 70 percent, fractional shortening at the
midwall of 56 percent, and a cardiac output of 2.81
liters per minute, with a left ventricular measure-
ment of 3.42 cm during diastole (50th percentile)
and 1.99 cm (25th percentile) during systole and
respective septal measurements of 0.59 cm (75th
percentile) and 0.81 cm (75th percentile).
The stimulus-induced myoclonus gradually sub-
sided after two months. The child’s motor and
mental development has been normal. Now, at 4.5
years of age, he continues to have increased muscle
bulk and strength, and he is able to hold two 3-kg
dumbbells in horizontal suspension with his arms
extended.
Several family members (Fig. 1D) have been re-
ported to be unusually strong. Family member II-3
was a construction worker who was able to unload
curbstones by hand. The 24-year-old mother of the
child (III-5) appeared muscular, though not to the
extent observed in her son; she did not report any
health problems. No family members aside from
the mother were available to provide samples for
genetic analysis.
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Figure 1. Photographs of the Child at the Ages of Six Days 
and Seven Months (Panel A), Ultrasonograms (Panel B) 
and Morphometric Analysis (Panel C) of the Muscles 
of the Patient and a Control Infant, and the Patient’s 
Pedigree (Panel D).
 
The arrowheads in Panel A indicate the protruding mus-
cles of the patient’s thigh and calf. In Panel B, an ultra-
sonographic transverse section (linear transducer, 10 
MHz) through the middle portion of the thigh reveals 
differences between the patient and a control infant of 
the same age, sex, and weight. VL denotes vastus latera-
lis, VI vastus intermedius, VM vastus medialis, RF rectus 
femoris, and F femur. In Panel C, retracings of the mus-
cle outlines and results of the morphometric analysis of 
the muscle cross-sectional planes of the two infants also 
reveal marked differences. Panel D shows the patient’s 
pedigree. Solid symbols denote family members who are 
exceptionally strong, according to information in their 
clinical history. Square symbols denote male family 
members, and circles female family members.
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uscle wasting and weakness are among the most common
 
 
 
in-
 
herited and acquired disorders and include the muscular dystrophies,
cachexia, and ag -related wasting. Since there is no generally accepted
treatment to i prove muscle bulk and strength, these conditions pose a substantial
burden to patients as well as to public health. Consequently, there has been consider-
able interest in a recently described inhibitor of muscle growth, myostatin, or growth/
differentiation factor 8 (GDF-8), which belongs to the transforming growth factor 
 
b
 
superfamily of secreted proteins that control the growth and differentiation of tissues
throughout the body. The myostatin gene is expressed almost exclusively in cells of
skeletal-muscle lineage throughout embryonic development as well as in adult ani-
mals and functions as a negative regulator of muscle growth.
 
1,2
 
 Targeted disruption of
the myostatin gene in mice doubles skeletal-muscle mass.
 
1
 
 Conversely, systemic over-
expression of the myostatin gene leads to a wasting syndrome characterized by ex-
tensive muscle loss.
 
3
 
 In adult animals, myostatin appears to inhibit the activation of
satellite cells, which are stem cells resident in skeletal muscle.
 
4,5
 
The potential relevance of myostatin to the treatment of disease in humans has been
suggested by studies involving 
 
mdx
 
 mi e, which carry a mutation in the dystrophin gene
and therefore serve as a genetic model of Duchenne’s and Becker’s muscular dystro-
phy.
 
6
 
 For example
 
, mdx
 
 mice that lacke  myost tin were foun  not only to be stronger
and more muscular than their
 
mdx
 
 counterparts with normal myostatin, but also to have
reduced fibrosis and fatty remodeling, suggesting mproved regeneration of us-
cle.
 
7
 
 Furthermore, injection of neutralizing monoclonal antibodies directed against
myostatin into either wild-type or 
 
mdx
 
 mice increases mus le mass and specific force,
suggesting that myostatin plays an important role in regulating muscle growth in adult
animals.
 
8,9
 
The function of myostatin appears to be conserved across species, since mutations
in the myostatin gene have been shown to be responsible for the “double-muscling”
phenotype in cattle.
 
10-13 
 
The phenotypes of mice and cattle lacking myostatin and the
high degree of sequence conservation of the predicted myostatin protein in many mam-
malian species have raised the possibility that myostatin may help regulate muscle
growth in humans. We report the identification of a myostatin mutation in a child with
muscle hypertrophy, thereby providing strong evidence that myostatin does play an im-
portant role in regulating muscle mass in humans.
A healthy woman who was a former professional athlete gave birth to a son after a nor-
mal pregnancy. The identity of the child’s father was not revealed. The child’s birth
weight was in the 75th percentile. Stimulus-induced myoclonus developed several
m
case report
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  a	  breed	  of	  beef	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  The	  Belgian	  Blue	  
has	  a	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  muta,on	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  gene	  which	  codes	  for	  the	  
protein,	  myosta,n.	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Racing Performance in Heterozygote Dogs
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Double muscling is a trait previously described in several mammalian species including cattle and sheep and is caused
by mutations in the myostatin (MSTN) gene (previously referred to as GDF8). Here we describe a new mutation inMSTN
found in the whippet dog breed that results in a double-muscled phenotype known as the ‘‘bully’’ whippet. Individuals
with this phenotype carry two copies of a two-base-pair deletion in the third exon ofMSTN leading to a premature stop
codon at amino acid 313. Individuals carrying only one copy of the mutation are, on average, more muscular than wild-
type individuals (p ¼ 7.43 3 10"6; Kruskal-Wallis Test) and are significantly faster than individuals carrying the wild-
type genotype in competitive racing events (Kendall’s nonparametric measure, s¼ 0.3619; p ’ 0.00028). These results
highlight the utility of performance-enhancing polymorphisms, marking the first time a mutation in MSTN has been
quantitatively linked to increased athletic performance.
Citation: Mosher DS, Quignon P, Bustamante CD, Sutter NB, Mellersh CS, et al. (2007) A mutation in the myostatin gene increases muscle mass and enhances racing
performance in heterozygote dogs. PLoS Genet 3(5): e79. doi:10.1371/journal.pgen.0030079
Introduction
The wide variety of behaviors and morphological types
exhibited among dog breeds and the overall low genetic
diversity within each breed make the dog an excellent genetic
system for mapping traits of interest [1,2]. Recently, owners of
whippets, an established racing-dog breed, have reported a
phenotype of heavy muscling occurring within the breed
(http://www.k9community.co.uk/forums/index.php). The typi-
cal whippet is similar in conformation to the greyhound, a
medium-sized sighthound, weighing about 9 kg and charac-
terized by a slim build, long neck, small head, and pointed
snout (Figure 1A) [3]. Heavily muscled dogs, termed ‘‘bully’’
whippets by breeders, have broad chests and unusually well-
developed leg and neck musculature (Figure 1C). ‘‘Bully’’
whippets are easily distinguished from their normal litter-
mates based on physical appearance alone (compare Figure
1A and 1C). Owners report that ‘‘bully’’ whippets do not have
any health abnormalities other than muscle cramping in the
shoulder and thigh. However, the dogs are often euthanized
at an early age as they do not conform to the American
Kennel Club breed standard. In addition, about 50% of
‘‘bully’’ whippets have a distinctive overbite.
The ‘‘bully’’ whippet phenotype is reminiscent of the
double muscling phenotype seen in other species that is
caused by mutations in the myostatin (MSTN) gene. Such
variants have been observed in mice [4], cattle [5,6], sheep [7],
and human, the latter described once in a German boy [8].
The myostatin protein has been shown to affect both the
amount and composition of muscle fibers. For instance, the
muscle mass of Mstn knockout mice is two to three times
greater than that of wild-type mice [9]. Furthermore, the
sequence of the MSTN gene is relatively conserved across
species [9]. Therefore, we chose to interrogate theMSTN gene
for possible mutations resulting in the ‘‘bully’’ whippet
phenotype.
Results
MSTN Genotypes in the Whippet
We sequenced the three exons and the majority of introns
of the MSTN gene in an initial set of 22 whippets. A 2-bp
deletion was discovered in the third exon of the MSTN gene
(Figure 2). This deletion removes nucleotides 939 and 940
within exon three and leads to a premature stop codon at
amino acid 313 instead of the normal cysteine, removing 63
aa from the predicted 375-aa protein. The lost cysteine is one
of several highly conserved cysteines known to form disulfide
dimers required for protein function [9].
Of the 22 whippets sequenced, all ‘‘bully’’ whippets tested
(n ¼ 4) were homozygous for the deletion (mh/mh) while all
dogs that sired or whelped a ‘‘bully’’ whippet (n ¼ 5) were
heterozygous for the deletion (mh/þ). None of the initial set of
13 normal-appearing whippets that lacked a family history of
the ‘‘bully’’ phenotype carried the deletion; these dogs were
designated wild type (þ/þ). An additional set of DNA samples
from 146 whippets (both racers and nonracers) were collected
at racing events and through the mail without regard to the
dogs’ family histories of the ‘‘bully’’ phenotype. These were
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type individuals (p ¼ 7.43 3 10"6; Kruskal-Wallis Test) and are significantly faster than individuals carrying the wild-
type genotype in competitive racing events (Kendall’s nonparametric measure, s¼ 0.3619; p ’ 0.00028). These results
highlight the utility of performance-enhancing polymorphisms, marking the first time a mutation in MSTN has been
quantitatively linked to increased athletic performance.
Citation: Mosher DS, Quignon P, Bustamante CD, Sutter NB, Mellersh CS, et al. (2007) A mutation in the myostatin gene increases muscle mass and enhances racing
performance in heterozygote dogs. PLoS Genet 3(5): e79. doi:10.1371/journal.pgen.0030079
Introduction
The wide variety of behaviors and morphological types
exhibited among dog breeds and the overall low genetic
diversity within each breed make the dog an excellent genetic
system for mapping traits of interest [1,2]. Recently, owners of
whippets, an established racing-dog breed, have reported a
phenotype of heavy muscling occurring within the breed
(http://www.k9community.co.uk/forums/index.php). The typi-
cal whippet is similar in conformation to the greyhound, a
medium-sized sighthound, weighing about 9 kg and charac-
terized by a slim build, long neck, small head, and pointed
snout (Figure 1A) [3]. Heavily muscled dogs, termed ‘‘bully’’
whippets by breeders, have broad chests and unusually well-
developed leg and neck musculature (Figure 1C). ‘‘Bully’’
whippets are easily distinguished from their normal litter-
mates based on physical appearance alone (compare Figure
1A and 1C). Owners report that ‘‘bully’’ whippets do not have
any health abnormalities other than muscle cramping in the
shoulder and thigh. However, the dogs are often eut aniz d
at an early age as they do not conform to the American
Kennel Club breed standard. In addition, about 50% of
‘‘bully’’ whippets have a distinctive overbite.
The ‘‘bully’’ whippet phenotype is reminiscent of the
double muscling phenotype seen in other species that is
caused by mutations in the myostatin (MSTN) ge e. Such
variants have been observed in mice [4], cattle [5,6], sheep [7],
and human, the latter described once in a German boy [8].
The myostatin protein has been shown to affect bot the
amount and composition of muscle fibers. For instance, the
muscle mass of Mstn knockout mice is two to three times
greater than that of wild-type mice [9]. Furthermore, the
sequence of the MSTN gene is relatively conserved across
species [9]. Therefore, we chose to interrogate theMSTN g ne
for possible mutations resulting in the ‘‘bully’’ whippet
phenotype.
Results
MSTN Genotypes in the Whippet
We sequenced the three exons and the majority of introns
of the MSTN gene in an initial set of 22 whippets. A 2-bp
deletion was discovered in the third exon of the MSTN gene
(Figure 2). This deletion removes nucleotides 939 and 940
within exon three and leads to a premature stop codon at
amino acid 313 instead of the normal cysteine, removing 63
aa from the predicted 375-aa protein. The lost cysteine is one
of several highly conserved cysteines known to form disulfide
dimers required for protein function [9].
Of the 22 whippets sequenced, all ‘‘bully’’ whippets tested
(n ¼ 4) were homozygous for the deletion (mh/mh) while all
dogs that sired or whelped a ‘‘bully’’ whippet (n ¼ 5) were
heterozygous for the deletion (mh/þ). None of the initial set of
13 normal-appearing whippets that lacked a family history of
the ‘‘bully’’ phenotype carried the deletion; these dogs were
designated wild type (þ/þ). An additional set of DNA samples
from 146 whippets (both racers and nonracers) were collected
at racing events and through the mail without regard to the
dogs’ family histories of the ‘‘bully’’ phenotype. These were
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Penetrance	  and	  Expressivity	  
•  We	  do	  not	  really	  know	  the	  penetrance	  or	  expressivity	  
of	  	  pre]y	  much	  ALL	  muta,ons	  in	  humans,	  as	  we	  have	  
not	  systema,cally	  sequenced	  or	  karyotyped	  any	  
gene,c	  altera,on	  in	  MILLIONS	  of	  people,	  nor	  
categorized	  into	  ethnic	  classes,	  i.e.	  clans.	  
•  There	  is	  a	  MAJOR	  clash	  of	  world-­‐views,	  i.e.	  does	  
gene,cs	  drive	  outcome	  predominately,	  or	  are	  the	  
results	  modiﬁed	  substan,ally	  by	  environment?	  i.e.	  is	  
there	  really	  such	  a	  thing	  as	  gene,c	  determinism	  for	  
MANY	  muta,ons?	  
For	  now,	  more	  eﬀort	  should	  be	  placed	  
on	  the	  following:	  
•  Rare,	  highly	  penetrant	  muta,ons	  running	  in	  families,	  
with	  cascade	  carrier	  tes,ng.	  
•  The	  genomic	  background	  is	  much	  more	  constant	  in	  
families.	  
•  The	  environmental	  background	  is	  some,mes	  more	  
constant	  in	  families.	  
•  This	  allows	  one	  to	  know	  much	  more	  about	  issues	  with	  
penetrance	  of	  rare	  variants	  in	  these	  families.	  
“The	  Na,onal	  Human	  Genome	  Research	  
Ins,tute	  is	  planning	  to	  fund	  the	  crea,on	  of	  a	  
single	  resource	  that	  would	  house	  and	  
disseminate	  data	  about	  poten,ally	  clinically	  
relevant	  gene,c	  variants	  that	  are	  being	  
unearthed	  by	  genomics	  research	  projects.”	  
	   	   	  -­‐July	  13,	  2012,	  Genome	  Web	  Daily	  New	  
Clinically	  Relevant	  Variants	  Resource,	  or	  CRVR	  
An	  alternate	  universe	  
•  Genomes	  sequenced	  by	  companies	  and	  academics	  with	  the	  
minimal	  standards	  in	  place	  (i.e.	  CLIA	  in	  America).	  
•  All	  data,	  including	  variant	  lists,	  added	  to	  “the	  cloud”	  that	  
consumers	  can	  access.	  
•  Consumers	  can	  go	  back	  and	  repeatedly	  look	  at	  their	  own	  
genome.	  
•  Consumers	  own	  and	  manage	  these	  data,	  and	  they	  can	  pay	  
anyone	  they	  like	  to	  help	  them	  interpret	  the	  data	  for	  them.	  
•  These	  are	  CONSUMERS,	  not	  pa,ents,	  and	  we	  need	  to	  move	  
away	  from	  paternalisCc	  medicine.	  
•  I	  am	  concerned	  that	  regula,on	  requiring	  delivery	  of	  gene,c	  
data	  by	  “physicians”	  will	  choke	  oﬀ	  and	  kill	  the	  genomic	  
revolu,on	  and	  individualized	  medicine.	  
One	  Solu,on	  
•  Require	  that	  all	  iniCal	  germline	  exome	  and	  whole	  genome	  
sequencing	  in	  live	  humans	  be	  performed	  in	  a	  CLIA-­‐cer,ﬁed	  or	  
other	  clinical-­‐grade	  manner.	  
•  I	  pray	  and	  hope	  that	  industry	  will	  collate	  and	  distribute	  
muta,ons	  in	  an	  interna,onal	  human	  varia,on	  database,	  
allowing	  for	  calcula,on	  of	  penetrance	  and	  extensive	  burden	  
tes,ng.	  
•  CLIA-­‐cer,ﬁed	  (clinical	  grade)	  sequencing	  up	  front	  allows	  
return	  of	  all	  data,	  including	  rare,	  highly	  penetrant	  muta,ons,	  
to	  families,	  facilita,ng	  carrier	  screening	  and	  counseling.	  
•  Require	  return	  of	  genomic	  data	  to	  par,cipants,	  allowing	  the	  
par,cipants	  to	  distribute	  and	  “crowd-­‐source”	  their	  own	  data.	  
•  Government	  should	  divert	  funds	  toward	  a	  10	  to	  100	  fold	  
increase	  for	  gene,c	  counselors,	  so	  that	  we	  can	  have	  
compassionate	  engagement	  with	  families.	  
Ancestry.com	  meets	  23andMe	  meets	  
Pa,entsLikeMe	  meets	  WGS?	  
Clinical	  Validity	  with	  Worldwide	  
Human	  Gene,c	  Varia,on	  “database”?	  
PaCentsLikeMe	  
Need	  to	  change	  the	  Tenor	  of	  the	  
debate	  
	  
•  Sequencing	  live	  humans	  without	  method	  in	  place	  to	  return	  results,	  
perhaps	  no	  longer	  acceptable?	  	  
•  I	  feel	  that	  it	  is	  ethically	  and	  morally	  unacceptable	  to	  sequence	  live	  humans	  
only	  in	  research	  setngs,	  par,cularly	  without	  gene,c	  counseling	  and	  
means	  for	  return	  of	  results	  in	  place.	  	  
•  The	  iniCal	  germline	  exome	  and/or	  whole	  genome	  sequencing	  for	  each	  
human	  should	  be	  performed	  in	  a	  clinical-­‐grade	  (CLIA-­‐cer,ﬁed)	  manner,	  
including	  for	  those	  samples	  at	  the	  major	  genome	  sequencing	  centers	  
involved	  in	  “complex	  disease”	  sequencing.	  
•  “What	  kind	  of	  work	  deemed	  as	  accepted	  today	  will	  be	  denounced	  by	  
future	  genera,ons?	  The	  ques,on	  is	  one	  that	  all	  researchers	  should	  bear	  in	  
mind,	  because	  history	  may	  judge	  them	  more	  harshly	  than	  their	  peers	  do.”	  
-­‐Nature	  editorial,	  February	  9,	  2012	  
Need	  Minimal	  Regulatory	  Standards!	  
In	  Choosing	  a	  Sperm	  Donor,	  a	  Roll	  of	  the	  Gene,c	  Dice	  
Sarah	  Phipps	  for	  The	  New	  York	  Times	  
	  
Jaxon	  Kretchmar,	  2,	  who	  was	  conceived	  with	  donated	  sperm,	  has	  cys,c	  ﬁbrosis.	  
	  
Pandora’s	  Baby	  
•  “It	  seemed	  to	  boil	  down	  to	  a	  struggle	  between	  
two	  compe,ng	  impulses:	  the	  crea,ve	  drive	  to	  
understand	  nature	  versus	  the	  conserva,ve	  
drive	  to	  impose	  limits	  and	  maintain	  the	  status	  
quo.”	  
Figure 4.	

	

Figure 4. NAT activity of recombinant hNaa10p WT or p.Ser37Pro 
towards synthetic N-terminal peptides. A) and B) Purified MBP-hNaa10p 
WT or p.Ser37Pro were mixed with the indicated oligopeptide substrates (200 
µM for SESSS and 250 µM for DDDIA) and saturated levels of acetyl-CoA 
(400 µM). Aliquots were collected at indicated time points and the acetylation 
reactions were quantified using reverse phase HPLC peptide separation. 
Error bars indicate the standard deviation based on three independent 
experiments. The five first amino acids in the peptides are indicated, for 
further details see materials and methods. Time dependent acetylation 
reactions were performed to determine initial velocity conditions when 
comparing the WT and Ser37Pro NAT-activities towards different 
oligopeptides. C) Purified MBP-hNaa10p WT or p.Ser37Pro were mixed with 
the indicated oligopeptide substrates (200 µM for SESSS and AVFAD, and 
250 µM for DDDIA and EEEIA) and saturated levels of acetyl-CoA (400 µM) 
and incubated for 15 minutes (DDDIA and EEEIA) or 20 minutes (SESSS and 
AVFAD), at 37°C in acetylation buffer. The acetylation activity was determined 
as above. Error bars indicate the standard deviation based on three 
independent experiments. Black bars indicate the acetylation capacity of the 
MBP-hNaa10p wild type (WT), while white bars indicate the acetylation 
capacity of the MBP-hNaa10p mutant p.Ser37Pro. The five first amino acids 
in the peptides are indicated. 
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•  @Katy_Read:	  Like	  many	  writers,	  I	  have	  rituals.	  
Before	  wri,ng,	  I	  pour	  some	  coﬀee,	  open	  the	  
window	  by	  my	  desk,	  and	  a]empt	  to	  read	  the	  
en,re	  internet.	  
